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Abstract 
Acute pancreatitis is an acute inflammation of the pancreas initiated by intracellular 
activation of pancreatic digestive enzymes. It is characterised by local and systemic 
activation of inflammatory cells, with overproduction of pro-inflammatory mediators. 
Systemic inflammation is accompanied by development of an anti-inflammatory 
counter-reaction that may result in impaired host immunity. It is believed that these 
inflammatory mediators play a significant role in the progression of local pancreatic 
inflammation into systemic disease with involvement of other organ systems. Usually 
acute pancreatitis is a mild, self-limited disease. However, some 20 to 30% of patients 
develop severe disease, with local pancreatic complications or systemic organ 
dysfunction or both. Because the development of vital organ failure is the major cause 
of morbidity and mortality in acute pancreatitis, early identification of patients likely 
to develop organ failure would be of clinical value. 
 
The aim of the present study was to find markers to predict development of organ 
failure as well as give insight into the development of immunosuppression in patients 
with acute pancreatitis. 
 
This clinical study consists of four parts. All patients studied were admitted to 
Helsinki University Central Hospital with acute pancreatitis. In the first study, serum 
levels of mast cell tryptase, vascular endothelial growth factor, and basic fibroblast 
growth factor were studied during the first week of hospitalisation in 70 patients, of 
whom 20 developed organ failure. In the second study, monocyte human leucocyte 
antigen (HLA)-DR expression was studied in 314 consecutive patients on admission. 
In the third study, plasma anti-inflammatory cytokines and monocyte HLA-DR 
expression were determined during their hospital stay in 27 and 47 patients with mild 
and severe disease, respectively; 20 patients with severe disease developed organ 
failure. In the fourth study, 19 prognostic markers were studied at hospital admission 
in 33 consecutive patients who developed organ failure and 99 matched control 
patients to find the best single marker and a combination of markers to accurately 
predict development of organ failure. 
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Our results show that organ failure usually develops early in the course of acute 
pancreatitis, suggesting that predictive tests should be carried out immediately on 
hospital admission. In patients who developed organ failure, circulating tryptase 
levels were higher than in other patients, indicating that mast cell activation may be 
involved in the pathophysiology of remote organ dysfunction. Furthermore, a 
compensatory anti-inflammatory reaction determined by the circulating anti-
inflammatory cytokines interleukin-6 or interleukin-10 developed early, reflected 
disease severity, and correlated with development of immunosuppression. Flow 
cytometric determination of monocyte HLA-DR expression was a useful method to 
monitor immunosuppression. Low HLA-DR expression predicted development of 
organ failure at least as well as did high C-reactive protein or acute physiology and 
chronic health evaluation (APACHE) II score. Failure to recover initially low HLA-
DR expression was related to secondary infections later in the course of acute 
pancreatitis. High circulating interleukin-6 and interleukin-10 levels within the first 
24 hours of disease onset may predict the development of organ failure, whereas at 
hospital admission, the combination of interleukin-10 more than 50 pg/ml or serum 
calcium less than 1.65 mmol/l predicted organ failure with better diagnostic accuracy 
than did any single marker or the APACHE II score. 
 
In conclusion, acute pancreatitis provoked systemic inflammation which began with 
systemic activation of inflammatory cells possibly including mast cells. Co-
occurrence of anti-inflammatory cytokines in the circulation with pro-inflammatory 
mediators preceded development of systemic manifestations and resulted in early 
deactivation of monocytes. Measurement of interleukin-10 in combination with 
calcium provided an accurate method to predict organ failure at hospital admission. 
Monitoring of monocyte HLA-DR expression in patients with organ failure may 
provide a means to predict secondary infections occurring later in the course of the 
disease. 
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Abbreviations 
ACD   acid-citrate-dextrose 
ALI   acute lung injury 
AP  acute pancreatitis 
APACHE acute physiology and chronic health evaluation 
ARDS   adult respiratory distress syndrome 
AST   aspartate aminotransferase  
AUC  area under curve 
bFGF   basic fibroblast growth factor  
C/B ratio cost/benefit ratio 
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CD   clusters of differentation 
CI   confidence interval 
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MCP  monocyte chemoattractant peptide 
MHC   major histocompatibility complex  
MIP   macrophage inflammatory protein 
MODS  multiple organ dysfunction score 
MODS  multiple organ dysfunction syndrome 
MOF   multiple organ failure 
NF  nuclear factor 
NO   nitric oxide 
PaCO2  arterial partial pressure of carbon dioxide 
PAF   platelet-activating factor 
PAI   plasminogen activator inhibitor 
PaO2  arterial partial pressure of oxygen 
PAR   protease-activated receptors 
PE   phycoerythrin  
PLA2  phospholipase A2 
RFU   relative fluorescence units 
ROC   receiver-operating characteristic 
sIL-2R  soluble interleukin-2 receptor 
SIRS   systemic inflammatory response syndrome 
TAP   trypsinogen activation peptide 
TGF  transforming growth factor 
TNF   tumour necrosis factor 
VCAM  vascular cell adhesion molecule 
VEGF   vascular endothelial growth factor 
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1 Introduction 
Acute pancreatitis (AP) is a common cause of acute abdominal pain and is the most 
frequent pancreatic disease, for which alcohol abuse and gallstone disease are the two 
most common causes (Lankisch et al. 2001). It is usually a mild, self-limited disease 
showing only minimal and transient systemic manifestations including fever, 
tachycardia, hypovolaemia or tachypnea. However, some 20 to 30% of patients 
develop severe disease with pancreatic complications including necrosis, abscess or 
pseudocysts, or systemic organ dysfunction (Bradley 1993). Systemic organ 
dysfunction may affect one or more remote organ systems. Respiratory failure and 
renal failure are the two types of organ dysfunction most commonly encountered 
(Heath et al. 1995). Development of vital organ dysfunction is, in AP, the major cause 
of morbidity and mortality (De Beaux et al. 1995). About half the deaths occur within 
the first week, typically from organ failure (McKay et al. 1999). Later in the course of 
the disease, secondary infections lead to a second attack of systemic inflammation, 
resulting in increase in organ dysfunctions and death (Bone 1996a). 
 
AP is an inflammation of the pancreas with inconsistent involvement of regional 
tissues and remote organ systems. Inflammation is initiated by intracellular activation 
of pancreatic proenzymes and autodigestion of the pancreas (Steer and Meldolesi 
1988, Grady et al. 1998). Irrespective of the aetiological factor, destruction of the 
pancreatic parenchyma induces an inflammatory reaction at the site of injury 
characterised by infiltration of activated leucocytes. Infiltrating inflammatory cells 
play a central role in determining AP severity (Steer 2002). Local leucocyte-derived 
production of inflammatory mediators may become amplified, resulting in systemic 
activation of inflammatory cells and overwhelming production of inflammatory 
mediators. This process is considered responsible for the systemic manifestations of 
the disease (Norman 1998). Although a number of inflammatory mediators in this 
process have been characterised, the exact pathophysiologic mechanisms that 
determine the course of the disease remain to be established. 
 
At present, no specific treatment exists that would prevent development of systemic 
complications in patients with AP. Several early supportive treatments or 
  
 
12
interventions may, however, be beneficial (Yousaf et al. 2003), making early 
identification of patients bound to develop organ dysfunction important. Tests 
available for prediction of the disease severity are in general considered inaccurate 
during the earliest phase of the disease. A new simple and rapid test is thus needed for 
identification of these high-risk patients so that their monitoring and intensive care 
can be initiated without delay. 
 
Increasing understanding of the pathogenesis of systemic inflammation and multiple 
organ dysfunction syndrome may provide us with drugs to inhibit development of 
organ dysfunction or ameliorate already developed physiological disturbances 
(Bernard 2003). In contrast to sepsis-related organ failures, a therapeutic window 
exists between onset of symptoms and development of organ dysfunction in AP 
(Norman 1998). Experimental studies suggest that introduction of anti-inflammatory 
treatment early enough may be able to prevent further development of organ 
dysfunction (Norman et al. 1995c, Rongione et al. 1997). An early predictive test 
would be essential for clinical studies of these future treatments. 
 
Immune-mediated immunosuppression may play an important role in the 
development of secondary infections in the later course of AP. Because treatment of 
patients with these late complications remains a challenge with high mortality rates, 
novel methods to diagnose and treat these patients are also needed. Monitoring of 
immunosuppression and even therapy that would restore impaired host defense 
mechanisms may provide additional tool for this clinical issue (Döcke et al. 1997). 
 
The main purpose of this clinical study was to find early prognostic tests to identify 
patients bound to develop organ failure. At first we explored whether the serum levels 
of mast cell tryptase and vascular endothelial growth factor (VEGF) correlate with the 
development of organ dysfunction. Secondly, an anti-inflammatory counter-reaction 
and development of immunosuppression were studied with relationship to clinical 
outcome. Thirdly, we investigated whether prognostic markers or a combination of 
these predict organ failure on hospital admission. 
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2 Review of the literature 
2.1 Historical background 
The term pancreas comes from the Greek words pan, all; kreas, flesh, but its origin 
has never been accurately determined. In 1889, pathologist Reginald Heber Fitz 
(1843-1913) was the first to provide a systematic description of clinical AP (Fitz 
1889, Leach et al. 1990). Only 7 years later did Hans Chiari (1896) postulate that the 
pathogenetic mechanism of AP was autodigestion (O´Reilly, 2001). Eugene Lindsay 
Opie (1873-1971) was the first to describe gallstones as an aetiological factor for AP 
in 1901 (Opie 1901, McClusky et al. 2002). The association between alcohol abuse 
and pancreatitis was described later by Symmers (1917). In the early twentieth 
century, the treatment recommended for AP was emergency surgery (Moynihan 
1925). Recognition of high mortality rates (between 50% and 78%) and following the 
invention of a test in 1927 to measure serum amylase levels (Elman 1927), a more 
conservative approach was adopted in the treatment of AP (Mikkelsen 1934) until the 
1970s, when early surgical treatment for severe AP was again adopted (McClusky et 
al. 2002). The following decades provided several surgical options including total 
pancreatectomy, open and closed peripancreatic drainage, open packing, blunt 
necrosectomy, staged reoperation necrosectomy with delayed primary closure over 
drains, and necrosectomy with continuous closed local lavage – all with variable 
success. 
 
The earliest surveys of respiratory and renal failure in AP were published in the mid-
twentieth century (Paxton and Payne 1944, Stein et al. 1959, Roseman et al. 1960). 
Adult respiratory distress syndrome (ARDS) in patients with AP was first described in 
1967 by Ashbaugh and colleagues. The first description of sequential multiple organ 
failure was published in the early 1970s concerning surgical patients (Tilney et al. 
1973). Edmondson and Berne were the first to suggest that measurement of a single 
biochemical factor (i.e., serum calcium) might be a useful predictor of outcome in AP 
(Edmondson and Berne 1944). In 1974, Ranson and co-authors provided several 
prognostic signs of severe AP, and further improvement in diagnosis and severity 
assessment of AP followed introduction of computed tomography (CT) (Haaga et al. 
1976, Kivisaari et al. 1983, Balthazar et al. 1990). Because of improved 
  
 
14
understanding of the mechanisms underlying the pathogenesis of AP and multiple 
organ dysfunction syndrome, and improved diagnostic methods and favourable results 
after conservative management during the last two decades, surgical treatment of AP 
has been limited mainly to those few patients with severe AP with infected pancreatic 
necrosis and not responding to intensive conservative treatment later in the course of 
the disease (Yousaf et al. 2003). 
 
2.2 Clinical manifestations and classification 
AP usually has an acute onset characterised by upper abdominal pain that may radiate 
to the back. Abdominal pain may be accompanied by nausea, vomiting, fever, and 
tachycardia. Abdominal findings in clinical examination vary from mild tenderness to 
rebound. Ileus and even shock may be present at admission (Ranson 1997). Rare 
clinical findings include bruising of the flank (Grey Turner’s sign) or periumbilical 
bruising (Cullen’s sign) (Dickson and Imrie 1984). In some cases, clinical 
presentation is atypical, with absence of abdominal pain (Wilson and Imrie 1988, 
Lankish et al. 1991). Laboratory examinations in most patients show leukocytosis and 
elevated pancreatic enzyme levels in blood or urine (Smotkin and Tenner 2002).  
 
Reported mortality rates for AP vary considerably in hospitalized series (2-22%), 
which can be explained by differing patient selection. In addition to in-hospital 
mortality, a third of patients with fatal AP are not admitted to hospital and are 
diagnosed post-mortem (Appelros and Borgstrom 1999, Andersson and Andren-
Sandberg 2003). Furthermore, 10% of severe AP patients surviving initial 
hospitalisation die within a few years (Halonen et al. 2003). The mortality rate 
increases dramatically in the elderly and is not affected by aetiology (McKay et al. 
1999, Eland et al.2000). Recurrent episodes seem to have a lower risk of death 
(Appelros and Borgstrom 1999), although conflicting results are also reported (Gullo 
et al. 2002). In epidemiological studies, the overall mortality rate of AP ranges from 1 
to 3/100 000 person years (Wilson and Imrie 1990, Appelros and Borgstrom 1999, 
Floyd et al. 2002). Case-mortality in population-based studies ranges from 7 to 15% 
(McKay et al. 1999, Eland et al. 2000, Floyd et al. 2002). Despite increasing 
incidence of AP, its mortality rate has been decreasing (Jaakkola and Nordback 1993, 
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McKay et al. 1999, Eland et al. 2000, Floyd et al. 2002), which may indicate either 
improved treatment or increased incidence of the mild AP with its minimal mortality. 
2.2.1 Mild acute pancreatitis 
A clinically based classification system for AP was established in an international 
symposium in Atlanta, in the USA, in 1992, in which AP was classified as either mild 
or severe (Bradley 1993). The majority (70 - 80%) of cases present with mild AP. The 
histological finding is interstitial oedema; peripancreatic fat necrosis may or may not 
be present. Patients with mild AP respond to appropriate conservative treatment with 
prompt normalization of physical signs and laboratory values. Mild AP is 
characterised by uneventful recovery, minimal organ dysfunction, and absence of 
pancreatic complications (Bradley 1993). 
2.2.2 Severe acute pancreatitis 
About 20 to 30% of patients develop severe AP (Steinberg and Tenner 1994), which 
is associated with remote organ failure or at least one local pancreatic complication, 
or both (Bradley 1993).  
2.2.2.1 Local pancreatic complications 
Local pancreatic complications include pancreatic necrosis, abscess, and pseudocyst. 
A diffuse or focal area of nonviable pancreatic parenchyma defines pancreatic 
necrosis, which is typically associated with peripancreatic fat necrosis; haemorrhage 
may be present. Microscopically, there is extensive interstitial fat necrosis with vessel 
damage, and necrosis affecting acinar cells, islet cells, and the pancreatic ductal 
system (Nevalainen and Aho 1992, Kloppel and Maillet 1993). Pancreatic necrosis 
usually develops within the first four days in the course of AP (Isenmann et al. 1993). 
Diagnosis of pancreatic necrosis is based on findings in dynamic contrast-enhanced 
CT (Kivisaari et al. 1983). Prerequisite for diagnosis are focal or diffuse, well-defined 
zones of non-enhanced (less than 30 Hounsfield units) pancreatic parenchyma that are 
larger than 3 cm or involve more than 30% of the pancreas (Balthazar et al. 1990). 
 
A pancreatic abscess is a circumscribed intra-abdominal collection of pus with a 
positive microbial culture located in the proximity of the pancreas. Purulent material 
contains little or no pancreatic necrosis. Pancreatic abscesses are considered to arise 
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as a consequence of limited pancreatic necrosis with subsequent liquefaction and 
secondary infection usually later in the course of severe AP, often at least four weeks 
after onset (Bittner et al. 1987). 
 
A pancreatic pseudocyst may occur as a result of AP and disruption of the pancreatic 
duct. It is a collection of extravasated pancreatic fluid enclosed by a wall of fibrous or 
granulation tissue, which arises at least four weeks after onset of AP (Bradley et al. 
1976). Fluid collections during the first four weeks of AP lack a defined inflammatory 
wall and are called acute fluid collections, most of which regress spontaneously, while 
some progress to become pseudocysts or abscesses (Bradley 1993). 
2.2.2.2 Organ failure 
Depending on the criteria for organ failure, it is associated with severe AP in 20 to 
80% of cases and is the major cause of morbidity and mortality (Heath et al. 1995, de 
Beaux et al. 1995, Tenner et al.1997). Organ failure develops early in the course of 
AP (Isenmann et al. 2001, Johnson et al. 2001) and is responsible for mortality within 
the first week, which accounts for about half the AP mortality (McKay et al. 1999). 
Organ failure in AP shows the same characteristics as organ failure induced by sepsis, 
major surgery, or trauma (Wilson et al. 1998). Lung injury, i.e., acute lung injury 
(ALI) or ARDS, is the most prominent organ failure and is present in the majority of 
patients with organ failure (Atabai and Matthay 2002, Vincent et al. 2002). Other 
organ systems that may be affected include the renal, hepatic, cardiovascular, 
haematologic, gastrointestinal, neurological (Deitch 1992), endocrine (Marik and 
Zaloga 2002), and immune systems (Kox et al. 2000).  
 
The term “multiple organ dysfunction syndrome” (MODS) was recommended by the 
consensus conference of the American College of Chest Physicians and the Society of 
Critical Care Medicine to define the presence of altered organ function in an acutely 
ill patient such that homeostasis cannot be maintained without intervention (Bone et 
al. 1992). The terms “multiple organ failure” (MOF) (Deitch 1992) or simply “organ 
failure” (Bradley 1993) has been used for the same clinical entity, which is 
characterised by sequential development of the dysfunction and eventually failure of 
at least one organ system. No uniformly accepted consensus criteria for multiple 
organ failure exist. The use of several different scoring systems including the MOF 
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score initially published by Goris and co-authors (1985), the multiple organ 
dysfunction score (MODS) (Marshall et al. 1995), and others (Vincent et al. 1996, Le 
Gall et al. 1996), or criteria (Bradley 1993) for defining organ failure makes 
comparison of studies difficult. In the Atlanta classification system, organ failure in 
AP is defined as shock (systolic blood pressure less than 90 mmHg), pulmonary 
insufficiency (PaO2, 60 mmHg or less), renal failure (creatinine level, higher than 177 
µmol/l after rehydration), or gastrointestinal bleeding (more than 500 ml/ 24 hours) 
(Bradley 1993). 
2.2.2.3 Secondary infections 
Patients with severe AP are susceptible to secondary infections including infected 
pancreatic necrosis, pancreatic abscess, and generalized infection like sepsis. 
Pancreatic necrosis becomes infected at an overall frequency of 30 to 70%, and 
becomes more common with duration of disease (Beger et al. 1986). Infected 
pancreatic necrosis is associated with prolonged hospital stay and increases mortality 
(Rau et al. 1997b). Gram-negative bacteria cause most infections, but one-third are 
polymicrobial, including also anaerobes and fungi. Bacterial species in pancreatic 
infections suggest that the intestine may be the main source of pathogens, but the 
biliary system may also serve as a route of bacterial contamination in biliary AP (Räty 
et al. 1998). Possible mechanisms to promote the passage of bacteria across the 
intestinal barrier include decreased bowel motility and overgrowth of indigenous 
microflora, impaired host immunity, and injury to the bowel mucosa due to MODS. 
Bacteria may then translocate into mesenteric lymph nodes and eventually into the 
bloodstream (Cicalese et al. 2001). 
 
2.3 Epidemiology 
Worldwide, the incidence of AP varies considerably: from 2/100 000 person years to 
73/100 000 person years, one of the highest incidences being in Finland (Bourke 
1975, Thomson et al. 1987, Jaakkola and Nordback 1993). Several studies have 
shown an increasing trend in annual incidence during recent decades (Jaakkola and 
Nordback 1993, Eland et al. 2000, Floyd et al. 2002). The prevalence of two main 
aetiological factors (gallstones and alcohol abuse) may explain variations and increase 
in incidence (Jaakkola and Nordback 1993), which may not be attributable only to 
improved diagnostic methods (Eland et al. 2000). Direct comparison of incidences is 
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difficult because of differing diagnostic criteria in these epidemiological studies 
(Dufour and Adamson 2003). Recurrent episodes of AP have a great impact on 
incidence values, accounting for over a third of all cases (Appelros and Borgstrom 
1999). AP is more prevalent in men and is relatively uncommon in children (Benifla 
and Weizman 2003). 
 
2.4 Aetiology 
Numerous aetiological factors have been associated with AP, but about 70 to 80% of 
patients have either gallstones or a history of alcohol abuse (Sakorafas and Tsiotou 
2000). Worldwide, these causes affect a respective 41% and 32% of victims 
(Lankisch et al. 2001), with considerable variation in the predominance of these two 
main aetiological factors among countries (Gullo 2002). Alcohol consumption 
correlates with incidence of alcoholic pancreatitis, the most common aetiological 
factor in Finland (Jaakkola and Nordback 1993, Räty et al. 2003). Females are more 
likely to have gallstones as an aetiological factor for AP (Lankisch et al. 2001), 
although men are more likely to develop AP than women when gallstone disease is 
present (Lowenfels et al. 2000). Other rare causes of AP are metabolic 
(hypercalcaemia, hyperlipidemia, toxins, drugs, genetic mutations in rare hereditary 
AP), mechanical obstruction (endoscopic retrograde cholangiopancreaticography or 
ERCP, pancreas divisum, post-trauma, pancreatic tumour, worms, foreign bodies, 
dysfunction or stenosis of the sphincter of Oddi, biliary sludge), vascular (ischaemia, 
vasculitis), infection, and inflammatory bowel disease (Sakorafas and Tsiotou 2000). 
In about 10% of cases aetiology is idiopathic. The aetiology of AP is likely 
multifactorial, including genetic factors, because only a minority of patients with 
common bile duct stones or suffering from alcohol abuse do develop AP (Singh and 
Simsek 1990). 
 
2.5 Pathogenesis of acute pancreatitis 
Pathogenesis of AP involves three steps: at first a triggering factor is needed to initiate 
pancreatic acinar cell injury by poorly understood mechanisms. Secondly, after 
several intracellular events, pancreatic proenzymes (zymogens) become activated 
intracellularly, resulting in acinar cell injury. Acinar cell injury is followed by local 
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inflammation of the pancreas, which involves activation of several inflammatory cells 
and release of inflammatory mediators. 
2.5.1 Triggering factors 
Mechanisms by which different aetiological factors initiate AP are incompletely 
understood. Initially, a common-channel theory was proposed as an explanation of 
how an impacted gallstone in the ampulla of Vater can induce AP by causing bile 
reflux into the pancreatic duct (Opie 1901). Later, experimental results demonstrated 
that pancreatic duct obstruction alone is capable of triggering AP (Lerch et al. 1993). 
Several possible sequels of duct obstruction, including refluxed biliary-pancreatic 
secretions, pancreatic duct hypertension, and/or aberrant acinar cell secretion, may 
lead to progression of AP (Lightner and Kirkwood 2001). The pathogenesis of 
alcoholic pancreatitis may involve several mechanisms not yet fully understood. One 
mechanism proposed is that alcohol or its oxidative or non-oxidative metabolites 
(Werner et al. 2002, Wilson and Apte 2003, Criddle et al. 2004) sensitize acinar cells 
to intracellular zymogen activation (Gorelick 2003). 
2.5.2 Intrapancreatic digestive enzyme activation 
Pancreatic digestive enzymes are stored in pancreatic acinar cells as inactive 
proenzymes (zymogens). Zymogens are synthesized in the endoplasmic reticulum and 
stored in zymogen granules in the apical pole of acinar cells. Under physiological 
conditions, zymogens are secreted into pancreatic fluid and pass via the pancreatic 
ductal system into the duodenum, where activation takes place by enteropeptidase. 
According to the current hypothesis, the crucial step in AP is intracellular activation 
of zymogens, especially trypsinogen, resulting in active trypsin, which is capable of 
activating other zymogens (Hofbauer et al. 1998). Zymogen activation is 
accompanied by secretory blockage of these activated digestive enzymes (Grady et al. 
1998). In experimental studies, the triggering event is immediately followed by an 
increase in cytosolic calcium ions, which is needed for further progression  (Raraty et 
al. 2000, Krüger et al. 2000). Secondly, defective sorting of newly synthesized 
proteins in the Golgi stack probably results in co-localization of zymogens and 
lysosomal hydrolases within cytoplasmic vesicles (Steer and Meldolesi 1988, Otani et 
al. 1998, Singh et al. 2001), where trypsinogen is catalytically activated by these 
lysosomal hydrolases (Halangk et al. 2000, Van Acker et al. 2002). Ultrastructurally, 
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zymogen granules on the apical pole of acinar cells are replaced by vacuoles, in which 
further zymogen activation takes place (Gorelick 2003). Activation of zymogens leads 
to acinar cell injury, and activated enzymes and their activation peptides escape into 
the interstitium of the pancreas and into the circulation.  
2.5.3 Inflammation 
Inflammation is a physiological protective response to tissue injury produced by 
mechanical (such as trauma, burns, surgery), chemical (such as AP) or microbial 
stimuli in infection. Inflammation is a complex system controlled by highly amplified 
humoral and cellular responses. Humoral responses include plasma-derived enzyme 
cascades like complement, kinin, coagulation or fibrinolytic cascades and numerous 
cell-derived mediators. Inflammatory cell activation leads to synthesis and release of 
soluble inflammatory mediators and altered expression of cell membrane-bound 
receptors and complexes (Delves and Roitt 2000). In the circulation, white blood cells 
(polymorphonuclear leucocytes, monocytes, and lymphocytes) and platelets are all 
involved in inflammatory processes. Macrophages and mast cells are present in 
tissues, and upon inflammation, circulating inflammatory cells also are sequestered in 
inflamed tissues. Vascular endothelial cells form a barrier between the circulation and 
tissues. In inflammatory processes, activation of endothelial cells is essential for 
inflammatory cell sequestration in tissues. 
2.5.3.1 Inflammatory cells 
Phagocytes 
Polymorphonuclear neutrophils, the most numerous leucocytes in the blood, play a 
pivotal role in acute inflammation. Activation of neutrophils is manifested by 
increased integrin CD11b/CD18 and decreased L-selectin expression on the cell 
surface. This altered adhesion-molecule expression facilitates neutrophil extravasation 
at the site of inflammation (Repo and Harlan 1999). Activated neutrophils secrete a 
wide variety of inflammatory mediators including the pro-inflammatory cytokines 
interleukin (IL)-1β, tumour necrosis factor (TNF)-α, and interferon (IFN)-γ and anti-
inflammatory cytokines like IL-1 receptor antagonist (IL-1ra), IL-6, and transforming 
growth factor (TGF)-β (Davies and Hagen 1997, Opal and Depalo 2000).  
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Figure 1. A. Pro-inflammatory reaction: phagocyte-endothelial cell interactions 
including rolling and adhesion, release of major pro-inflammatory mediators by 
activated inflammatory cells, T-helper (Th) cell activation and differentiation into Th1 
cells, activation of circulating monocytes, and tissue destruction mediated by 
activated neutrophils releasing reactive oxygen species (ROS) and proteases. B. Anti-
inflammatory reaction: Release of anti-inflammatory cytokines, T-helper (Th) cell 
activation and differentiation into Th2 cells, deactivation of circulating monocytes. 
MHC II – major histocompatibility complex II; ICAM – intercellular adhesion 
molecule; GM-CSF – granulocyte-macrophage colony-stimulating factor; IFN – 
interferon; IL – interleukin; IL-1ra – interleukin-1 receptor antagonist; PAF – platelet-
activating factor; TNF – tumour necrosis factor 
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In addition to cytokine production, neutrophils also produce lipid mediators such as 
platelet-activating factor (PAF) and leukotriene B4, both of which share pro-
inflammatory activities (Bulger and Maier 2000). Neutrophils mediate their 
destructive effect through generating reactive oxygen species, through phagocytosis, 
and by releasing proteolytic enzymes (Dallegri and Ottonello 1997) (Figure 1A). 
 
Circulating monocytes, upon migration into tissues, undergo tranformation into tissue 
macrophages. In inflammatory processes, tissue macrophages play an important role 
in modulating and chemoattracting other inflammatory cells because of being the 
main source of pro-inflammatory cytokines (IL-1β, TNF-α, IL-12) (Norman et al. 
1995b, Fink and Norman 1996), chemokines (IL-8, monocyte chemoattractant peptide 
MCP-1) (Strieter et al. 1999), major anti-inflammatory cytokines (IL-1ra, IL-6, IL-10) 
(Opal and DePalo 2000), and lipid mediators (PAF, leukotrienes, prostaglandins, and 
thromboxane) (Bulger and Maier 2000). The principal task of 
monocytes/macrophages like neutrophils is phagocytosis; they also generate reactive 
oxygen species. Moreover, monocytes/macrophages play a fundamental role in the 
immune response by presenting antigens to lymphocytes during the development of 
specific immunity (Delves and Roitt 2000). Monocytes/macrophages express major 
histocompatibility complex (MHC)-class II antigens on the cell surface (Koppelman 
et al. 1997). Expression of MHC class II antigen (human leucocyte antigen, HLA-DR) 
on monocytes/macrophages is a prerequisite in the presentation of phagocytosed- 
processed antigen to T-helper cells for the elaboration of a specific immune response 
(Wolk et al. 2000, Tonegawa 1988) (Figure 1A).  
T-lymphocytes 
Lymphocytes represent 20% of circulating leucocytes, most of which are T-cells, of 
which two-thirds are CD4+ (helper) T-cells and the rest CD8+ (cytotoxic) T-cells. 
Helper T-cells play a pivotal role in development of the specific immune response and 
mediate their effect either by activating macrophages or by activating B-lymphocytes. 
Helper T-cells are activated by antigen presented on MHC class II molecules on 
antigen-presenting cells (Tonegawa 1988). Activated helper T-cells differentiate into 
either Th1 or Th2 cells, depending on cytokine stimulus (Kelso 1995) (Figure 1). 
Initially, macrophage-derived pro-inflammatory cytokine IL-12 drives differentiation 
into Th1 cells, which produce macrophage-activating molecules including IFN-γ, 
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granulocyte-macrophage colony-stimulating factor (GM-CSF), and TNF-α. Later, 
anti-inflammatory cytokines (IL-4 and IL-10) favour differentiation into Th2 cells, 
which inhibit macrophage functions and Th1 responses (through IL-4, IL-10, and IL-
13), resulting in the down-regulation of the inflammatory response (Mosmann and 
Sad 1996). Th2 cells produce B-lymphocyte-activating molecules promoting B-cell-
derived antibody production. Cytotoxic T-cells are activated by antigen presented on 
MHC class I molecules and kill their targets by inducing apoptosis. Activated T-cells 
produce IL-2, which is the primary stimulator of T-cell proliferation and 
differentiation (Spellberg and Edwards 2001). 
Mast cells 
Mast cells are found closely apposed to the vasculature in essentially all tissues. A 
vast number of stimuli are able to activate mast cells including substance P, 
complement components, bradykinin, and chemokines (MCP-1 and macrophage 
inflammatory protein MIP-1α). Upon activation, mast cells release from their 
intracellular granules vasoactive agents such as histamine, pro-inflammatory 
cytokines such as TNF-α and proteolytic enzymes such as tryptase (Schwartz 1994) 
(Figure 1A). Mast cell activation can promote vascular endothelium P- and E-selectin 
and the intercellular adhesion molecule ICAM-1 expression (Thorlacius et al. 1994, 
Kubes and Granger 1996) and, specifically, mast cell-derived tryptase can initiate 
endothelial cell activation by cleaving endothelial PAR-2 (Molino et al. 1997, 
Coughlin 2000). Early P-selectin-mediated leucocyte-endothelial-cell rolling after 
tissue trauma is dependent on mast cell degranulation and activation of endothelial 
cell PAR-2 (Lindner et al. 2000). Indeed, mast cells have been shown to play a critical 
role in host defense against bacterial infections by modulating neutrophil influx at 
sites of infection (Echtenacher et al. 1996, Malaviya et al. 1996).  In addition, mast 
cells are an important source of anti-inflammatory cytokine IL-4 and interact with T-
helper cell differentiation (Metcalfe et al. 1997). 
Platelets 
Platelets are activated parallel with endothelial cell and coagulation cascade activation 
during inflammation. Thrombin can mediate activation of platelets through PAR-1 
receptors, which results in increased adhesion molecule expression such as P-selectin 
on platelet plasma membrane (Coughlin 2000). PAF and interactions with adhesion 
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molecules on activated endothelial cells may also trigger platelet activation (Repo and 
Harlan 1999). Activated platelets become adherent, which leads to platelet 
aggregation and subsequent degranulation of intracellular granules. During 
degranulation, platelets release a number of cytokines (Wagner and Burger 2003) and 
growth factors like VEGF (Weltermann et al. 1999). Activated platelets may adhere to 
circulating phagocytes, and promote leucocyte-endothelial cell adhesion (Repo and 
Harlan 1999). In conjunction with fibrin, platelets may form a haemostatic plug 
(Wagner and Burger 2003) and contribute to microcirculatory dysfunction in multiple 
organ dysfunction syndrome (Gawaz et al. 1997). 
Endothelial cells  
Endothelium is the lining between blood and tissues. Endothelial cells mediate and 
modulate vascular permeability, microcirculation, migration of leucocytes into 
tissues, and blood coagulation. In inflammation, the endothelial cell lining becomes 
permeable, allowing fluid and plasma protein extravasation. A number of mediators 
can increase vascular permeability, e.g., bradykinin, substance-P, leukotrienes, and 
VEGF, some of which are implicated in the pathogenesis of AP (Figini et al. 1997, 
Grady et al. 2000). In addition, a number of substances (IL-1β, TNF-α, PAF, 
thrombin, trypsin, tryptase) can activate endothelial cells, which leads to altered 
expression of cell-surface proteins, increased secretion of pro-inflammatory cytokines 
and chemokines, and increased vascular permeability (Zimmerman et al. 1999). 
 
Leucocyte recruitment to the site of inflammation involves interactions with 
endothelial cells. This multi-step process mediated by adhesion molecules involves 
leucocyte rolling, adhesion, and migration (Figure 1A). Within minutes, upon an 
inflammatory stimulus, endothelial cells activate and express P-selectin, PAF, and 
von Willebrand factor (Zimmerman et al. 1999, Aird 2003). This is initiated by 
activation of the endothelial cell-bound protease-activated receptors PAR-1 and PAR-
2 (Coughlin 2000). Expression of E-selectin and IL-8 follows within 2 to 3 hours after 
cytokine IL-1β and TNF-α activation (Zimmerman et al. 1999). Immunoglobulin 
superfamily protein (i.e., ICAM-1 and vascular cell adhesion molecule VCAM-1) 
expression is also induced upon activation. Leucocytes express constitutively L-
selectin, and interaction of these endothelial cell selectins and leucocyte selectins 
initiates rolling of leucocytes in the microcirculation. Rolling promotes activation of 
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leucocytes by endothelial surface-associated chemokines and chemoattractants such 
as PAF and IL-8. Upon activation, L-selectin is shed from the cell surface and 
replaced by the integrin CD11b/CD18 which binds to the ICAM-1 and thus results in 
firm adhesion of leucocytes to endothelial cells. Leucocyte adherence to endothelium 
causes increased microvascular permeability (Edens and Parkos 2003), and finally 
these firmly attached leucocytes transmigrate across the endothelium in postcapillary 
venules (Repo and Harlan 1999).  
 
Under normal physiologic conditions, endothelium prevents activation of blood 
coagulation by several mechanisms (Hack and Zeerleder 2001). Inflammatory 
endothelium, however, turns into a procoagulant surface within hours by losing its 
anticoagulant properties and by introducing expression of tissue factor that can initiate 
the coagulation cascade. Activated endothelium also produces and releases 
plasminogen activator inhibitor (PAI)-1, which inhibits fibrinolysis (Aird 2003). 
Altered endothelial cell adhesion molecule expression may promote platelet adhesion 
and activation and consequently formation of intravascular platelet aggregates. 
 
Microvascular blood flow is regulated by endothelium by production of both 
vasodilators (nitric oxide, NO, and prostacyclin) and vasoconstrictors (endothelins). A 
number of inflammatory mediators can increase production of NO which results in 
vasodilation (Hack and Zeerleder 2001). On the other hand, stimulated endothelial 
cells also produce vasoconstricting endothelins, elevated levels of which have been 
detected in critically ill patients (Wanecek et al. 2000). Although some of the classical 
signs of inflammation (erythema and heat) result from vasodilatation, vasoconstriction 
may become more important in the development of organ dysfunction and pancreatic 
necrosis (Foitzik et al. 1998). 
 
2.5.3.2 Humoral mediators 
Pro-inflammatory cytokines 
Cytokines, soluble low molecular-weight proteins secreted not only by inflammatory 
cells but also by many different cell types, play an important role in regulating the 
immune response with a wide range of biological effects. Cytokine signalling can be 
autocrine, paracrine or endocrine, and cytokines can be assigned according to their 
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effects to either a pro-inflammatory or an anti-inflammatory group, although some of 
them share both properties. IL-1β and TNF-α are the principal cytokines promoting 
inflammatory responses (Dinarello 2000) but IL-2, IL-12, IL-18, IFN-γ, and GM-CSF 
also share pro-inflammatory activities (Figure 1A).  
 
Cells that are typically involved in the immune response can produce IL-1β, most 
importantly the monocyte-macrophage cell line. IL-1β is synthesized as the inactive 
precursor pro-IL-1β and is activated by the caspase-1/interleukin-1-converting 
enzyme (ICE), which also activates pro-IL-18 (Fantuzzi and Dinarello 1999). The 
principal feature of IL-1β is stimulation of arachidonic acid metabolism. Activation of 
the IL-1 receptor by IL-1β promotes nuclear translocation of nuclear factor (NF)-κB, 
leading to increased gene expression of a number of pro-inflammatory mediators 
including cytokines, chemokines, type II phospholipase A2 (PLA2), and adhesion 
molecules (Dinarello 2000, Abraham 2000). One of the most important properties of 
IL-1β involves its ability to activate the vascular endothelium and thus facilitate the 
mobilization, activation, and accumulation of leucocytes for specific localized 
immune responses (Zimmerman et al. 1999). 
 
Like IL-1β, TNF-α is a multifunctional cytokine acting as a first-line mediator in the 
pro-inflammatory cytokine cascade (Dinarello 2000). The main source for TNF-α is 
activated macrophages, but many other cell types can produce it. IL-1β and TNF-α 
share many biological properties including activation of endothelium (Pober et al. 
1996) and promotion of the synthesis of other pro-inflammatory mediators such as IL-
8 and PAF (Dinarello 2000). TNF-α is also a potent inducer of anti-inflammatory 
mediators such as IL-6 and IL-10, resulting a negative feedback loop (Oberholzer et 
al. 2002). TNF-α signalling occurs through two different receptors, and in patients 
with AP, soluble forms of the two also occur in high concentrations in the circulation 
(deBeaux et al. 1996a). 
 
IL-2, produced by activated T-lymphocytes, acts in an autocrine or paracrine fashion 
through the IL-2 receptor (IL-2R) to stimulate growth and activation of T-
lymphocytes (Spellberg and Edwards 2001). Like other interleukin receptors, it exists 
in a circulating form. Soluble IL-2R (sIL-2R) is released after T-cell stimulation, can 
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be measured in the circulation, and reflects T-cell activation (Rubin et al. 1985, Rubin 
and Nelson 1990). 
Chemokines 
Cytokines with chemotactic properties are called chemokines. These make up a 
family of small (8–10 kDa), inducible, secreted cytokines with chemotactic and 
activating effects on various leucocyte subsets. They provide the key stimulus for 
directing leucocytes to areas of injury (Adams and Lloyd 1997). A number of 
chemokines have been identified, including IL-8, epithelial neutrophil-activating 
protein-78 (ENA-78), the growth-related oncogene-α (GRO-α), MCP-1, and MIP-1 
and -1 (Strieter et al. 1999). IL-8 is one of the most potent mediators of neutrophil 
chemotaxis in this family of molecules. The early-response cytokines, TNF-α and IL-
1β, are key molecules for inducing IL-8, which is produced by an array of both 
inflammatory and other cells types including endothelial cells (Striter and Kunkel 
1994). 
Anti-inflammatory cytokines 
Anti-inflammatory cytokines control the pro-inflammatory cytokine response in 
concert with soluble cytokine receptors. Under physiological conditions, these 
cytokine inhibitors limit the potentially deleterious effects of sustained or excess 
inflammatory reactions. Principal anti-inflammatory cytokines include the IL-1ra, IL-
4, IL-6, IL-10, IL-11, IL-13, and TGF-β (Opal and DePalo 2000) (Figure 1B).  
 
IL-10 is the most potent anti-inflammatory cytokine (Opal et al. 1998). It inhibits Th1 
cytokine production, and down-regulates pro-inflammatory cytokine and chemokine 
synthesis in monocytes and macrophages (Opal and DePalo 2000). It also promotes 
the shedding of TNF receptors into the circulation (Joyce et al. 1994). IL-10 down-
regulates MHC class II cell-surface expression on monocytes (Koppelman et al. 
1997), which results in monocyte anergy and immunosuppression. IL-6 has been 
regarded as a pro-inflammatory cytokine, but recently it has been shown to act 
predominantly as an anti-inflammatory cytokine (Opal and DePalo 2000). IL-6 is a 
potent inducer of acute-phase protein responses in the liver. It also attenuates 
synthesis of IL-1β and TNF-α (Xing et al. 1998) and promotes synthesis of IL-1ra 
and release of soluble TNF receptor (Tilg et al. 1994). 
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IL-1ra, a specific antagonist to IL-1β, binds competitively to the IL-1 receptor and 
thus blocks IL-1-mediated responses at receptor level; concentrations over 100-fold 
those of IL-1β can be measured in the circulation (Dinarello 1998). IL-4 is a 
pleiotropic cytokine which inhibits Th1 responses and suppresses pro-inflammatory 
cytokine and chemokine production of monocytes/macrophages; it also stimulates 
synthesis of IL-1ra (Brown and Hural 1997). IL-11 attenuates pro-inflammatory 
cytokine synthesis in macrophages (Trepicchio et al. 1997). IL-13 down-regulates the 
production of IL-1β, TNF-α, IL-8, and MIP-1α. In contrast to IL-10, it upregulates 
MHC class II antigens on monocytes (de Waal Malefyt et al. 1993).  
Others 
Other humoral mediators of inflammation include complement components; these 
mediate inflammation by increasing blood vessel permeability, vasodilatation, 
neutrophil adhesion and activation, and chemotaxis (Hartwig et al. 2001). Kinins such 
as bradykinin are small vasoactive peptides generated by enzyme cascades and are 
closely linked to the clotting and complement cascades. Their vasoactive properties 
include vasodilatation and increased vascular permeability (Griesbacher et al. 2003). 
A number of lipid mediators are also produced during inflammation, including 
prostanoids (e.g., prostaglandins), leukotrienes, and PAF. They are not stored in 
tissues, but are synthesized within seconds in response to stimuli (Bulger and Maier 
2000). One, PAF, has a number of pro-inflammatory effects including phagocyte and 
platelet activation, activation of endothelial cells, and enhancement of vascular 
permeability (Zhao et al. 2003). PLA2, the key and rate-limiting enzyme of 
arachidonic acid metabolism, generates substrates for a number of lipid mediators 
(Bulger and Maier 2000). Increased circulating concentrations of the extrapancreatic 
isoform PLA2-IIA have been detected in many inflammatory diseases, including AP 
(Grönroos and Nevalainen 1992, Nevalainen et al. 1993, 2000), and it plays an 
important role in development of systemic inflammatory response syndrome (SIRS) 
(Bone et al. 1992, Hietaranta et al. 1999) and of distant organ dysfunction in AP 
(Grönroos and Nevalainen 1992, Tsukahara et al. 1999). 
 
Evidence is also increasing that VEGF may participate in inflammatory processes. 
VEGF expression is induced by hypoxia (Tuder et al. 1995) and cytokines (Cohen et 
al. 1996, Thickett et al. 2002), and it is released from activated neutrophils (Gaudry et 
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al. 1997) and from platelets during clotting (Weltermann et al. 1999). It directly 
increases vascular permeability and induces endothelial cell-adhesion molecule 
expression (Senger et al. 1983, Hippenstiel et al. 1998, Kaner et al. 2000), thus 
supporting the rolling and adhesion of leucocytes; it is also chemotactic for mast cells 
(Gruber et al. 1995). In addition to vascular permeability, VEGF induces angiogenesis 
(Senger et al. 1993). Another angiogenic factor in vivo is basic fibroblast growth 
factor (bFGF). Expression of the bFGF gene is increased in the pancreas of patients 
with AP and may be involved in pancreas regeneration (Ebert et al. 1999). 
  
2.5.4 Local inflammation and acinar cell death 
Acinar cell injury triggers local inflammation of the pancreas, which is characterised 
by sequestration of neutrophils within the pancreas and by oedema (Nevalainen and 
Aho 1992). Acinar cell apoptosis or necrosis or both are present. Mild oedematous 
pancreatitis is associated with acinar cell apoptosis, whereas the predominant finding 
in severe necrotizing AP is necrosis (Bhatia 2004). The mechanisms of acinar cell 
apoptosis and necrosis are poorly understood, and several mechanisms may be 
involved. Following acinar cell injury, activation of transcription factor NF-κB within 
acinar cells leads to expression of many pro-inflammatory mediators including TNF-
α (Steinle et al. 1999). In addition, PAF is very likely generated by phospholipase A2, 
which hydrolyzes membrane phospholipids that eventually lead to the release of PAF 
from acinar cells (Zhou et al 1993). Both PAF and TNF-α have been implicated also 
in acinar cell apoptosis (Gukovskaya et al. 1997, Sandoval et al. 1996). Intra-acinar 
cell caspase activation may also play a role in mediating apoptosis in AP 
(Gukovskaya et al. 2002). Infiltrating neutrophils may be responsible for acinar cell 
necrosis, through several mechanisms including release of proteolytic enzymes and 
production of reactive oxygen species (Dallegri and Ottonello 1997, Bhatia 2004). 
Neutrophil-derived reactive oxygen species have been shown to exacerbate pancreatic 
injury by facilitating trypsinogen activation (Gukovskaya et al. 2002, Steer 2002). 
Probably the most likely mechanism in pancreatic necrosis is the inflammation-
induced microvascular dysfunction that leads to tissue ischaemia and eventually to 
necrosis (Sanamura et al. 1998, Foitzik et al. 2002). 
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The pivotal role of neutrophils in AP is well documented (Sandoval et al.1996), 
although other cell types are also involved in the activation, chemoattraction, and 
sequestration of neutrophils. These include macrophages, acinar cells, endothelial 
cells, T-lymphocytes (Demols et al. 2000), nerve endings, and possibly mast cells 
(Braganza 2000). In addition to TNF-α and PAF production, injured acinar cells 
release active protelytic and lipolytic enzymes such as trypsin, elastase, 
carboxypeptidase A, and lipase, which may also play a role in inflammatory system 
activation (Jaffray et al. 2000a). Macrophages and infiltrating neutrophils are the main 
source of pro-inflammatory cytokines (e.g., TNF-α and IL-1β) in the pancreas 
(Norman et al. 1995b, Fink and Norman 1996). Pancreatic elastase can induce 
macrophage-derived cytokine and chemokine production (Zhang et al. 2003); trypsin 
may activate endothelial cells via PAR-2 receptors (Couglin 2000) and is able to 
activate complement (Acioli et al. 1997). 
 
Substance P and neurokinin are released from nerve endings during the early course 
of experimental AP, and these may contribute to increased vascular permeability 
either directly through endothelial cells or via mast-cell activation (Grady et al. 2000, 
Bhatia et al. 2003). Activation of the kallikrein-kinin system also plays an important 
role in the early increase in vascular permeability in AP. Acinar cells probably release 
kallikrein, which catalyses kininogens into kinins such as bradykinin that affect 
vascular tone and permeability (Griesbacher et al. 2003). 
 
2.6 Pathogenesis of multiple organ dysfunction syndrome 
2.6.1 Systemic inflammatory response syndrome 
Systemic inflammation in AP is considered to contribute to the development of distant 
organ dysfunction. Local inflammation is generally tightly controlled at the pancreas. 
Loss of local control or an overly activated inflammatory response results in an 
exaggerated systemic response characterised by systemic release of both pro-
inflammatory and anti-inflammatory cytokines and activation of circulating 
leucocytes. It is accompanied by endothelial cell activation in distant organs. 
Clinically, this response is defined as SIRS (Bone et al. 1992) and is characterised by 
two or more of the criteria presented in Table 1. 
  
 
31
 
Table 1. Criteria for systemic inflammatory response syndrome (Bone et al. 1992) 
Body temperature  >38 ºC or <36 ºC  
Heart rate >90 beats per minute 
Respiratory rate >20 breaths per minute or PaCO2 <4.3 kPa 
Leucocyte count >12 x 109/l or <4 x 109/l, or 10% immature forms 
PaCO2 – arterial partial pressure of carbon dioxide 
2.6.1.1 Primary event 
The severity of local pancreatic inflammation correlates with development of 
systemic inflammation. Local inflammation triggers the systemic inflammatory 
response by a mechanism that is poorly understood, but it may involve systemic 
release of the pro-inflammatory cytokines IL-1β and TNF-α (Fink and Norman 1995, 
Norman et al. 1995b, Norman 1998) or other soluble pro-inflammatory mediators 
(Denham et al. 1997). IL-1β and TNF-α levels correlate with severity in both 
experimental (Gloor et al. 1998b) and clinical AP (Exley et al. 1992, Chen et al. 
1999a, Mayer et al. 2000), and specific antagonisms of both of these, as well as 
indirect inhibition by anti-inflammatory cytokine IL-10, attenuate systemic 
inflammatory response and subsequent organ dysfunction (Norman et al. 1995c, 
Hughes et al. 1996, Kusske et al. 1996). Although a number of studies support the 
theory that these pro-inflammatory cytokines serve as a link between local and 
systemic inflammation, other factors may also be involved. Recently, pancreatic 
elastase has been shown in AP to stimulate pro-inflammatory cytokine synthesis of 
tissue macrophages, and thus provide an alternative mechanism of systemic activation 
of inflammation (Jaffray et al. 2000b, 2000c, Murr et al. 2002). Trypsin and activation 
of circulating trypsinogen in AP may also contribute to development of lung injury 
(Hartwig et al. 1999).  
2.6.1.2 Amplification  
Experimental studies have shown that during AP, pro-inflammatory cytokines are 
synthesized also in distant organs and that this begins several hours later than 
synthesis of these mediators in the pancreas (Norman et al. 1997). This 
extrapancreatic cytokine production contributes considerably to systemic cytokine 
levels (Gloor et al. 2000). From the pancreas, pro-inflammatory mediators are 
released into portal venous blood, and to a lesser extent into the lymphatic and 
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systemic circulation via the thoracic duct (Montravers et al. 1995). Portal venous 
blood enters the liver, which has been shown to play an essential role in development 
of the subsequent multiple organ failure (Closa et al. 1999, Dhainaut et al. 2001). In 
AP, the liver may be the source of elevated systemic levels of PLA2-IIA (Nevalainen 
et al. 2000, Talvinen et al. 2001). In the liver, tissue macrophages (i.e., Kupffer cells) 
up-regulate pro-inflammatory cytokine production (Gloor et al. 2000).  Blockage or 
inhibition of Kupffer cell cytokine production in experimental AP reduces systemic 
cytokine levels, ameliorates lung injury (Folch et al. 2000, Gloor et al. 2000), and 
improves survival (Gloor et al. 1998). Blockade of the action of early-acting cytokines 
(TNF-α and IL-1β) has beneficial effects on distant organ injury in experimental 
settings (Norman et al. 1995a, Hughes et al. 1996). Tissue-derived amplification 
results in high tissue concentrations of pro-inflammatory cytokines, although plasma 
concentrations are substantially lower due to their short half-life (Beutler et al. 1985). 
2.6.1.3 Distant organ injury  
The crucial step in development of distant organ injury is activation of endothelial 
cells by pro-inflammatory mediators (Strieter and Kunkel 1994). Activated 
endothelium facilitates neutrophil extravasation and activation (Repo and Harlan 
1999) in conjunction with chemokines (Strieter et al. 1999). In tissues, neutrophils 
promote pro-inflammatory cytokine production (Abraham 2003) and mediate tissue 
injury through generation of reactive oxygen species and proteolytic enzymes 
(Dallegri and Ottonello 1997). In severe experimental AP, increased expression of 
endothelial cell adhesion molecules occurs in the lungs (Lundberg 2000), and 
blockade of leucocyte-endothelial cell interaction prevents sequestration of 
neutrophils and ameliorates lung injury (Frossard et al. 1999, Lundberg et al. 2001) 
and also improves survival (Inoue et al. 1995). Neutrophil-endothelial cell adhesion 
induces increased endothelial cell permeability (Edens and Parkos 2003), leading to 
accumulation of protein-rich extracellular fluid that disturbs gas exchange in the lungs 
(Sznajder and Wood 1991), impairs oxygen delivery to tissues (Leach and Treacher 
2002), and results in circulatory hypovolaemia with adverse haemodynamic effects 
(Isenmann et al. 2003). Procoagulant endothelium and activation of platelets may 
dispose to formation of a haemostatic plug (Aird 2003) that, in conjunction with 
microcirculatory dysfunction (Menger et al. 2001, Foitzik et al. 2002), ultimately can 
lead to tissue ischaemia and result in irreversible organ damage. 
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2.6.2 Compensatory anti-inflammatory response syndrome 
2.6.2.1 Anti-inflammatory cytokines 
With synthesis and release of pro-inflammatory mediators, anti-inflammatory 
cytokines and specific cytokine inhibitors are concomitantly produced. During 
systemic inflammation, they may either provide insufficient control over pro-
inflammatory activities that ultimately lead to distant organ dysfunction or may 
overcompensate and inhibit the immune response, rendering the host at risk for 
systemic infection (Bone 1996a). High circulating levels of the anti-inflammatory 
cytokines IL-6, IL-10, IL-11, and IL-1ra have been documented in experimental (van 
Laethem et al. 1998, Gloor et al.2000) and clinical AP (Mayer et al. 2000, de Beaux et 
al. 1996, Simovic et al. 1999, Chen et al. 1999). Gene knockout models of IL-10 and 
IL-6 have shown that both are important in down-regulating pro-inflammatory 
cytokine production in AP; the absence of either anti-inflammatory cytokine results in 
worse survival rates (Gloor et al. 1998, Cuzzocrea et al. 2002). Although during AP a 
pro-inflammatory reaction is likely to predominate in tissues, in the circulation, anti-
inflammatory cytokines prevail over pro-inflammatory ones (Mayer et al. 2000, 
Cavaillon et al. 2001, Dugernier et al. 2003). Because the synthesis and systemic 
release of anti-inflammatory cytokines is regulated partly by pro-inflammatory 
cytokines (Opal and DePalo 2000), high circulating anti-inflammatory cytokine levels 
may reveal an overwhelming pro-inflammatory reaction in tissues.  
 
Genetic factors may play an important role in regulating the anti-inflammatory 
response: IL-1ra polymorphism contributes to susceptibility to severe sepsis (Fang et 
al. 1999), and a polymorphic allele in the IL-10 gene is associated with lower 
stimulated interleukin-10 release and increased mortality in the critically ill (Lowe et 
al. 2003).   
2.6.2.2 Monocyte deactivation and immunosuppression 
A compensatory anti-inflammatory response contributes to development of 
immunosuppression, which renders the host susceptible to secondary infections. 
Patients with severe AP show in skin testing an impaired response to recall antigens, 
denoting a state of cellular immunosuppression (Garcia-Sabrido et al. 1989). 
Defective host defense mechanisms include functional disturbances in monocytes and 
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macrophages that include persistent decrease in HLA-DR expression and diminished 
synthesis of pro-inflammatory cytokines (Döcke et al. 1997). IL-10 may be 
responsible to some extent for a decreased monocyte HLA-DR expression 
(Koppelman et al. 1997, Klava et al. 1997, Sachse et al. 1999, Fumeaux and Pugin 
2002) leading to impaired antigen presentation capacity which suppresses helper T-
cell activation (Tonegawa 1988, Wolk et al. 2000). Decreased HLA-DR expression is 
associated with adverse outcome including septic complications and increased 
mortality in trauma and sepsis and in surgical patients (Livingston et al. 1988, 
Hershman et al. 1990, Cheadle et al. 1991, van den Berk et al. 1997, Tschaikowsky et 
al. 2002). Moreover, in patients with AP, decreased monocyte HLA-DR expression is 
related to disease severity (Richter et al. 1999, Gotzinger et al. 2000, Kylänpää-Bäck 
et al. 2001b) and to septic complications later in the course of the disease (Satoh et al. 
2002). According to the two-hit hypothesis of MODS, septic complications in patients 
with initial overactive SIRS may lead to an exaggerated secondary inflammatory 
response and possibly to death (Bone 1996a). 
 
2.7 Diagnostic methods 
No definitive single method exists to diagnose AP. Its diagnosis is based on clinical 
presentation in conjunction with laboratory tests or radiology or both. The serum or 
plasma amylase level is increased within 2 to 12 hours of onset of AP and returns to 
normal within 3 to 5 days, whereas lipase rises within 4 to 8 hours but remains 
elevated for 8 to 14 days (Tietz et al. 1993). Elevated amylase is not specific for AP 
(Clavien et al. 1989), but the specificity for serum amylase in determining AP can be 
increased by using a cut-off of more than 2- to 3-fold the normal upper limit (Smotkin 
and Tenner 2002). Urine amylase level or the pancreas-specific isoenzyme of amylase 
level in plasma can also be measured (Clave et al. 1995). Levels of serum or urinary 
trypsinogen-2 are elevated in AP (Hedström et al. 1996a, Hedström et al. 1996b), and 
a rapid urine test is available for diagnosis (Kemppainen et al. 1997, Kylänpää-Bäck 
et al. 2000). Contrast-enhanced CT is a highly specific method to diagnose AP 
(Clavien et al. 1988), but in mild forms of the disease findings may be normal 
(Balthazar et al. 1994), and in the most severe forms of the disease, impaired renal 
function may limit use of the contrast medium due to its nephrotoxicity.  
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In these circumstances, magnetic resonance imaging may provide an alternative 
method with similar results (Hirota et al. 2002, Arvanitakis et al. 2004). Contrast-
enhanced CT is the gold standard for diagnosis of pancreatic necrosis (Balthazar 
2002); it is useful in localizing abscesses (Mithöfer et al. 1997) and may show the 
presence of gas in necrotic tissue or in fluid collections, indicating infection. 
However, diagnosis of infectious complications is based on positive microbiological 
culture or Gram staining obtained either by fine-needle aspiration or from a surgical 
sample (Rau et al. 1997). 
 
2.8 Prediction of disease severity 
2.8.1 Background 
Although no specific therapy for AP is available today, early identification of patients 
who will develop a severe form of the disease has clinical importance. Some 
interventions such as emergency ERCP and endoscopic sphincterotomy may be 
beneficial in severe biliary AP (Neoptolemos et al. 1988, Fan et al. 1993b), and for 
patients with severe AP, early intensive fluid resuscitation and monitoring may be of 
benefit (Brown et al. 2002), as is the case in patients with sepsis (Rivers et al. 2001). 
Delayed admission to an intensive care unit after hospital admission (Brivet et al. 
1999) and delayed transferred admission to a specialist centre (de Beaux et al. 1995) 
have been shown to increase the risk of death. During the first 48 hours, clinical 
assessment alone of severe AP has shown low sensitivity (34% to 47%) but high 
specificity (Wilson et al. 1990); therefore, several methods have been developed to 
improve prediction of the clinical course of AP. 
2.8.2 Scoring systems 
Ranson and co-workers (1974) provided the first prognostic criteria (Table 2) for 
predicting severe AP. Since then, a modification for biliary aetiology (Ranson 1982) 
plus other criteria described by Imrie and colleagues (Imrie or Glasgow score) have 
been available (Imrie et al. 1978, Osborne et al. 1981, Blamey et al. 1984). The 
drawback of these scoring systems is a delay of 48 hours in characterising disease 
severity. Other scoring systems including APACHE II (Knaus et al. 1985, Wilson et 
al. 1990) and APACHE III (Knaus et al. 1991, Williams and Simms 1999) have been 
used in prediction of outcome in AP with results similar to those of the Ranson score 
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(Chatzicostas et al. 2002, Eachempati et al. 2002). APACHE II can be used on 
admission to hospital, although its complexity limits its routine use (Toh et al. 2000). 
Multiple organ dysfunction scores have also served for prediction of outcome of 
severe AP (Halonen et al. 2002), but because they were developed to describe the 
severity of MODS, they are not useful in early prediction of severe AP. 
 
Table 2. Early objective prognostic signs in AP determined by Ranson in 1974. 
At admission or diagnosis 
Age > 55 years 
White blood cell count > 16 x 109/l 
Blood glucose level > 200 mg/dl (> 11.1 mmol/l) 
Serum lactic dehydrogenase concentration > 350 IU/l 
Serum glutamic oxaloacetic transaminase > 250 Sigma-Frankel units/dl 
During initial 48 hours 
Haematocrit decrease > 10% 
Blood urea nitrogen increase > 5 mg/dl (> 1.8 mmol/l) 
Serum calcium level < 8 mg/dl (< 2 mmol/l) 
Arterial partial pressure of oxygen < 60 mmHg (< 8 kPa) 
Base deficit > 4 mmol/l 
Estimated fluid sequestration > 6000 ml 
 
2.8.3 Laboratory tests 
A great number of laboratory tests have been subjected to examination in predicting 
the course of AP. These include tests for markers of inflammation and for acute phase 
proteins, pancreatic enzymes and derivatives, and for other markers; some of these 
tests are widely available in routine laboratory diagnostics. 
2.8.3.1 Acute phase proteins 
Among acute phase proteins, CRP has been extensively studied in AP (Puolakkainen 
et al. 1987, Wilson et al. 1989). The peak CRP value is usually reached within 48 to 
72 hours of disease onset and predicts severe AP at least as well as do complex 
scoring systems (Wilson et al. 1989, Chen et al. 1999). However, the increase in CRP 
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relatively late in the course of AP makes it inefficient for early assessment of severity 
(Sandström and Borgström 2002). Although CRP values of >150 mg/l 48 h after onset 
of symptoms indicate severe AP (Dervenis et al. 1999), the optimal CRP cut-off level 
in predicting severe AP depends on the timing of measurement (Müller et al. 2002, 
Sandström and Borgström 2002), and for prediction of organ failure cut-off level may 
differ. Serum amyloid-A is another acute phase protein shown to predict severe AP, 
performing at least as well as CRP (Pezzilli et al. 2000, Mayer et al. 2002). 
2.8.3.2 Inflammatory mediators  
 The prognostic roles of a variety of inflammatory mediators in AP have been studied 
extensively. Among pro-inflammatory cytokines, high IL-1β and IL-18 levels may 
have an impact on prediction of severe disease (Mayer et al. 2000, Rau et al. 2001, 
Wereszczynska-Siemiatkowska 2002), whereas levels of TNF-α are usually 
undetectable in clinical samples (Exley et al. 1992, Paajanen et al. 1995). Although 
elevated levels of IL-12 are documented in patients with AP, little is known about its 
role in predicting severity (Pezzilli et al. 1999). Circulating levels of soluble cytokine 
receptors such as TNF-receptors and sIL-2R rise early, are related to systemic 
complications in AP, and may be more accurate predictors than is CRP (de Beaux et 
al. 1996a, Mayer et al. 2000). IL-8 and other chemochines such as GRO-α, ENA-78, 
and MCP-1 have also been tested in prediction of a complicated course of AP, and 
show good predictive power (Rau et al. 1997a, Shokuhi et al. 2002, Rau et al. 2003).  
 
Several studies of AP have shown IL-6 to be an early marker of severity (Viedma et 
al. 1992, de Beaux et al. 1996, Brivet et al. 1999, Simovic et al. 1999). Elevation of 
circulating IL-6 precedes the acute phase response (Leser et al. 1991, Heath et al. 
1993) and may predict systemic complications and death (Mayer et al. 2000). 
Compared to pro-inflammatory cytokines, anti-inflammatory cytokines such as IL-6 
might serve as more useful factors for early prediction of prognosis (Chen et al. 
1999a). High circulating IL-1ra levels occur in patients with severe AP (Brivet et al. 
1999), and serum IL-1ra may serve as an early marker of severe AP (Mayer et al. 
2000). Several studies have shown that high circulating IL-10 is related to severe AP 
and fatal outcome (Mayer et al. 2000, Simovic et al. 1999, Brivet et al. 1999, Chen et 
al. 1999), although some conflicting data also exist (Pezzilli et al. 1997). IL-10 levels 
peak within the first 24 hours of disease onset and thus may provide a better signal 
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than CRP in early assessment of severity (Chen et al. 1999). Although elevated serum 
IL-11 levels appear in patients with severe AP, in its prediction, IL-11 appeared 
inferior to IL-10 (Chen et al. 1999).  
 
Procalcitonin, a marker of systemic inflammation and sepsis (Vincent 2000), has also 
been studied in patients with AP. Several studies (Rau et al. 1997a, Kylänpää-Bäck et 
al. 2001a, 2001c), but not all (Frasquet et al. 2003), indicate its possible role in 
predicting severe AP. Elevated catalytically active PLA2 levels reflect severity of AP 
(Puolakkainen et al. 1987, Viedma et al. 1992). Although pancreatic parenchyma also 
secretes PLA2 in AP, now it is known that elevated levels of catalytically active PLA2 
in AP are mainly of non-pancreatic origin, representing mainly an inflammation-
inducible type II PLA2 (Nevalainen et al. 1993, Hietaranta et al. 1999). 
 
Several markers of endothelial cell activation such as soluble forms of adhesion 
molecules (E-selectin, P-selectin, ICAM-1) and soluble trombomodulin are elevated 
in AP and may serve as predictors of the complicated course of the disease 
(Kaufmann et al. 1999, Powell et al. 2001, Mantke et al. 2002, Wereszczynska-
Siemiatkowska et al. 2003), although some inconsistency exists (Kingsnorth et al. 
1995, Kylänpää-Bäck et al. 2001c). An early event in AP is phagocyte activation, 
confirmed by elevated polymorphonuclear elastase concentration (Uhl et al. 1991) or 
by increased monocyte or neutrophil surface antigen CD11b expression (Kylänpää-
Bäck et al. 2001b). Phagocyte activation has been shown to reflect disease severity 
and may serve as an early predictor of severe AP (Wereszczynska-Siemiatkowska et 
al. 2003). A decrease in monocyte HLA-DR expression occurs early in the course of 
AP, reflects disease severity (Kylänpää-Bäck et al. 2001b, Richter et al. 1999), and 
may be a predictive marker of sepsis (Satoh et al. 2002), but it has not been evaluated 
in early prediction of systemic complications.  
2.8.3.3 Pancreatic proenzymes and derivatives 
Although circulating amylase levels are not helpful in assessment of AP severity 
(Ranson 1982), many other pancreas-derived substances have been demonstrated to 
predict severe disease. These include trypsinogen-2 (Hedström et al. 1996b, 
Lempinen et al. 2001), trypsinogen activation peptide (TAP) (Neoptolemos et al. 
2000, Kemppainen et al. 2001), carboxypeptidase B activation peptide 
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(CAPAP)(Müller et al. 2002), and trypsin-2-alpha-1-antitrypsin complex (Hedström 
et al. 2001). The advantage of these markers is that they can be detected early in the 
course of the disease; in addition, they are specific for AP. Compared to CRP, both 
urinary TAP and trypsinogen-2 seem to be slightly better in predicting severe AP 
(Lempinen et al. 2003, Neoptolemos et al. 2000), providing, however, only a marginal 
benefit over CRP (Windsor 2000). 
2.8.3.4 Miscellaneous 
Laboratory markers included among the Ranson criteria may also be used 
independently or in different combinations for predicting severe AP (Fan et al. 
1993a). Low platelet count (Ranson et al. 1977) and high serum creatinine and 
aspartate aminotransferase (AST) may also indicate severe AP (Fan et al. 1993a). All 
these markers are signs of AP’s systemic manifestations. High levels of creatinine or 
urea reflect renal dysfunction. Hyperglycaemia may be a consequence of increased 
gluconeogenesis in hepatocytes (Dhainaut et al. 2001) and of impaired endocrine 
function of the pancreas. Lactate dehydrogenase (LDH) is an intracellular enzyme 
detectable in virtually all tissues. A study of LDH isoenzymes in AP suggests that 
elevated levels are mainly of extrapancreatic origin (Chen et al. 1992) and thus may 
reflect cell damage in distant organs such as the lungs. Hypocalcaemia in sepsis and 
AP may be a consequence of sequestration of circulating calcium and albumin into 
extracellular space due to increased microvascular permeability (Bhattacharya et al. 
1985, Carlstedt et al. 2000), although other mechanisms may be involved, as well 
(Zaloga 2000). Low serum calcium alone has been shown to predict organ failure 
within 48 hours after ERCP (Kawa et al. 2000). However, markers that reflect 
systemic alterations in homeostasis may not be predictive of organ dysfunction, but 
instead suggest its dynamic nature (Cryer et al. 1999, Buter et al. 2002). 
2.8.4 Radiology 
Contrast-enhanced CT is not only diagnostic, but can serve as a prognostic tool. 
Determination of pancreatic necrosis (Kivisaari et al. 1983), its extent (Isenmann et al. 
1999) or its localization to the head of the pancreas (Kemppainen et al. 1996) may 
indicate a more severe course. The Balthazar CT grading and severity index correlates 
with clinical outcome in AP (Balthazar et al. 1985, Balthazar et al. 1990), and in 
predicting severe AP, CT severity index may be even better than other severity 
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indexes (Chatzicostas et al. 2003). However, CT is inaccurate in predicting organ 
failure (Chatzicostas et al. 2003), because organ failure occurs in only half the 
patients with pancreatic necrosis (Tenner et al. 1997). MRI could also serve in 
severity assessment with an accuracy similar to that of CT and may prove useful in 
clinical situations where CT is contraindicated (Arvanitakis et al. 2004).  
 
2.9 Treatment 
No specific medical treatment for AP exists. Treatment is mainly conservative, 
consisting of fluid resuscitation in the early phase of the disease, monitoring of organ 
function, and supportive treatment for organ failures (Yousaf et al. 2003). Results 
from three trials concerning ERCP in biliary AP (Neoptolemos et al. 1988, Fan et al. 
1993b, Folsch et al. 1997) suggest that early ERCP and endoscopic spincterotomy are 
mandatory for patients with cholangitis or biliary obstruction.  Several studies (Sainio 
et al. 1995, Nordback et al. 2001) including meta-analyses (Villatoro et al. 2004) have 
shown that prophylactic antibiotic treatment in severe AP reduces mortality and risk 
for infected necrosis. Recently, the first double-blind placebo-controlled trial 
involving patients with severe AP (Isenmann et al. 2004) showed no benefit from 
prophylactic ciprofloxacin-metronidazole combination in severe AP; that there were 
only five patients with infected necrosis in the control group suggests, however, that 
the series were overcrowded with mild cases. Although enteral nutrition seems to be 
well tolerated (McClave et al.1997) and may reduce infectious complications and 
severity of AP (Kalfarentzos et al. 1997, Windsor et al. 1998, Gupta et al. 2003), data 
are insufficient to allow firm conclusions as to its effectiveness and safety (Al-Omran 
et al. 2003).  
 
Pancreatic necrosis should be managed non-operatively (Bradley and Allen 1991, 
Foitzik et al. 1995). Surgical necrosectomy should be considered in cases of infected 
pancreatic necrosis (Rau et al. 1997b, Beger and Isenmann 1999), although non-
operative management in some of those patients may be successful (Nordback et al. 
2001, Adler et al. 2003). Patients with abdominal compartment syndrome (Gecelter et 
al. 2002) or with uncontrollable intra-abdominal haemorrhage or gut necrosis benefit 
from early surgical intervention, but for other indications the consensus is that it is 
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best to delay surgery; no generally accepted consensus exists, however, on the exact 
indications for and timing of any intervention. 
 
Several experimental studies and clinical trials have tried to discover medical 
treatment to prevent development of multiple organ dysfunction or ameliorate already 
existing multiple organ failure. In experimental models of AP, anti-inflammatory 
therapy has shown promising results in preventing severe AP (Norman et al. 1995a, 
Rongione et al. 1997) and subsequent organ failure and death (Hughes et al. 1996), 
but clinical trials have shown inconsistent results or have failed (Kingsnorth et al. 
1995, McKay et al. 1997, Johnson et al. 2001, Deviere et al. 2001, Dumot et al. 2001) 
– resembling the results of anti-inflammatory trials in patients with sepsis (Fisher et 
al. 1994, Freeman and Natanson 1995).  
 
Among possible ways to inhibit systemic inflammation and the development of organ 
dysfunction in the complex network of pro-inflammatory and anti-inflammatory 
mediators and intercellular interactions, are anti-inflammatory therapy with IL-10 
(Kusske et al. 1996, Rongione et al. 1997), IL-1ra (Norman et al. 1995a, Tenaka et al. 
1995), anti-TNF antibody (Hughes et al. 1996), or PAF antagonist (Kingsnorth et al. 
1995, McKay et al. 1997, Johnson et al. 2001), or anti-adhesion therapy with anti-
ICAM-1 antibody (Lundberg et al. 2001). Activated protein C has both antithrombotic 
and anti-inflammatory properties and has shown promising results in treatment of 
severe sepsis (Bernard 2003) and might also prove beneficial in severe AP. 
Endothelin receptor blockage can reduce capillary leakage in AP and improve 
microcirculation (Foitzik et al. 1998, Eibl et al. 2002).  
 
It is possible that in the complex network of inflammation, no single method is 
sufficient to prevent organ failure, and an early administration of combination of 
drugs, each with a distinct mechanism of action, may produce better results (Norman 
1998). However, in clinical AP, patients usually present at a fairly late stage of the 
disease, when SIRS and organ dysfunction are already present (Johnson et al. 2001). 
Organ dysfunction may thus not be preventable, although some therapies can inhibit 
organ deterioration. Later in the course of AP, a compensatory anti-inflammatory 
reaction results in immunosuppression, and anti-inflammatory therapies may become 
harmful (Opal et al. 1998, Oberholzer et al. 2002). In order to recover from 
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immunosuppression, patients may instead benefit from pro-inflammatory treatment 
(Volk et al. 1996, Döcke et al. 1997, Kox et al. 1997), a fact which makes it important 
to monitor patients’ immunoinflammatory state (Volk et al. 1999). 
 
2.10 Summary 
The inflammatory basis of AP and subsequent organ failure is indisputable, although 
exact mechanisms remain to be established. In addition to the inflammatory mediators 
already known, in the pathogenesis of AP, other factors may also be involved. The 
compensatory anti-inflammatory response syndrome and immunosuppression may 
play important roles in the development of infectious complications in patients with 
AP, and their clinical relevance needs to be evaluated. In predicting severity of AP, 
inflammatory mediators seem promising. However, most studies involving predictive 
markers have ignored the timing of development of organ failure and are predicting 
outcome when organ failure may already have occurred (Cryer et al. 1999). This was 
the case in a recent multi-center trial of the PAF-antagonist Lexipafant, which 
predicted severe AP as an APACHE II score 7, which led to inclusion of patients 
most of whom already had organ dysfunction; this ruined the primary end-point of the 
study (Johnson et al. 2001). Most studies with predictive markers have predicted 
severe AP according to the Atlanta classification, although the clinically more 
relevant issue would have been prediction of organ failure. Moreover, some studies 
have been mainly descriptive, have lacked any comparison to the gold standard, and 
have drawn conclusions from a relatively small number of patients without a 
significant difference between markers. Additional studies are therefore needed to 
address these issues. 
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3 The present investigation 
 
3.1 Aims of the study 
 
The main purpose of the present study was to find markers or a marker profile to 
predict the development of organ failure in patients with AP. Specific aims were: 
 
1. To explore whether serum levels of mast cell-derived tryptase and VEGF 
correlate with development of organ dysfunction in AP.  
2. To study the time-course of humoral and cellular markers of 
immunosuppression in relationship to outcome of AP. 
3. To investigate whether prognostic markers or their combination predicts organ 
failure in AP and when these markers should be measured. 
 
3.2 Materials and Methods 
3.2.1 Patients 
The local ethics committee approved the study protocols, and informed consent was 
obtained from each patient. All patients studied had AP and were admitted to Helsinki 
University Central Hospital within 72 hours of symptom onset. The first study 
included 70 non-consecutive patients with AP admitted between August 1997 and 
May 2000; 31 had mild disease; of the 39 with severe AP, 21 developed organ failure. 
The second study included 314 consecutive AP patients admitted between September 
1998 and July 2001. In the third study, we collected prospectively 238 consecutive 
patients admitted between August 1998 and October 2000; 147 had mild and 91 had 
severe disease; 20 of the latter developed organ failure. The study included the first 
consecutive 27 of the 147 patients with mild AP, the first consecutive 27 of the 71 
patients with severe AP with local complications only, and all 20 patients who 
developed organ failure. The fourth case-control study was based on 351 consecutive 
AP patients admitted between August 1998 and January 2002. Of these, 33 developed 
organ failure and were included in the study as cases. Three age- and sex-matched 
controls for each case, with admission dates closest to that of the case, were selected 
from among the remaining 318 AP patients, resulting in 99 control patients. 
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3.2.2 Diagnosis and classification 
Diagnosis of AP was based on typical clinical findings including acute onset of 
epigastric pain, nausea and vomiting, and elevated serum amylase concentration at 
least 3-fold the upper reference limit or was based on typical appearance of AP on 
computed tomography, or was based on a combination of these criteria. Patients were 
retrospectively categorised into those with mild AP or severe AP according to the 
Atlanta classification (Bradley 1993). Patients with severe disease were further 
subcategorised into those with only local complications, recovering without organ 
failure, versus those developing organ failure. Organ failure was defined as 
respiratory failure necessitating mechanical ventilation or renal failure necessitating 
haemodialysis, or both. Criteria for initiating mechanical ventilation were tachypnoea 
(respiratory rate > 35/minute) or need for inspiratory oxygen fraction (FiO2) > 0.6 in 
order to maintain arterial partial pressure of oxygen (PaO2) > 8 kPa, or both. 
Haemodialysis was started in patients with significant reduction in renal function 
indicated by increased concentrations of serum creatinine (> 300 mmol/l) and serum 
urea (> 40 mmol/l) and progressive metabolic acidosis (pH < 7.28) in serial 
measurements with or without anuria or oliguria (urine output < 500 ml /24 hours). 
3.2.3 Scoring systems 
Three scoring systems were used to describe patients’ clinical condition. Appropriate 
physiological and laboratory data were collected to calculate Ranson score (Table 2) 
(Ranson et al. 1974) (I, II, III), Multiple Organ Dysfunction Score (MODS) (Table 3) 
(Marshall et al. 1995) (I, II, III), and APACHE II score (Table 4) (Knaus et al. 1985) 
(I-IV). 
 
Table 3. Multiple Organ Dysfunction Score (MODS) (Marshall et al. 1995) 
   SCORE   
Organ system 0 1 2 3 4 
Respiratory: PaO2/FiO2, mmHg 
                                       (kPa) 
>300 
(>40) 
226-300 
(30.1-40) 
151-225 
(20.1-30) 
76-150 
(10.1-20) 
75 
(10) 
Renal: Serum creatinine, µmol/l 100 101-200 201-350 351-500 >500 
Hepatic: Serum bilirubin, µmol/l 20 21-60 61-120 121-240 >240 
Cardiovascular: PAR, l/min 10 10.1-15 15.1-20 20.1-30 >30 
Haematological: platelet count (E9/l) >120 81-120 51-80 21-50 20 
Neurological: Glasgow Coma Score 15 13-14 10-12 7-9 6 
FiO2, fraction of inspired oxygen; PaO2, arterial partial pressure of oxygen; PAR, pressure adjusted heart rate = heart rate multiplied by the ratio 
of central venous pressure to the mean arterial blood pressure 
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Table 4. APACHE II score (Knaus et al. 1985) 
 High abnormal range Low abnormal range 
Physiological variable    4 3 2 1 0 1 2 3 4 
Temperature, rectal (oC) 41 39-40.9  38.5-38.9 36-38.4 34-35.9 32-33.9 30-31.9 29.9 
Mean arterial pressure (mmHg) 160 130-159 110-129  70-109  50-69  49 
Heart rate 180 140-179 110-139  70-109  55-69 40-54 39 
Respiratory rate 50 35-49  25-34 12-24 10-11 6-9  5 
Oxygenation          
  a)FiO2>0.5 A-aDO2 (kPa) 
  A-aDO2=FiO2x95-PaCO2-PaO2 
66.7 46.7-66.6 26.7-46.6  <26.6     
  b)FiO2<0.5 PaO2     >9.3 8.1-9.3  7.3-8.0 <7.3 
Arterial pH 7.7 7.6-7.69  7.5-7.59 7.33-7.49  7.25-7.32 7.15-7.24 <7.15 
Serum sodium (mmol/l) 180 160-179 155-159 150-154 130-149  120-129 111-119 110 
Serum potassium (mmol/l) 7 6.0-6.9  5.5-5.9 3.5-5.4 3.0-3.4 2.5-2.9  <2.5 
Serum creatinine (µmol/l) 300 169-299 124-168  53-123  52   
Haematocrit (%) 60  50-59.9 46-49.9 30-45.9  20-29.9 <20  
Leucocyte count (E9/l) 40  20-39.9 15-19.9 3-14.9  1.0-2.9 <1  
Glasgow Coma Score (GSC) 
  Score=15 – actual GCS 
         
Age points: age 44, 0 points; 45-54, 2 points; 55-64, 3 points; 65-74, 5 points; and 75, 6 points  
FiO2, fraction of inspired oxygen; A-aDO2, alveolar-arterial oxygen difference; PaO2, arterial partial pressure of oxygen; PaCO2, arterial partial 
pressure of carbon dioxide 
 
3.2.4 Analytical methods 
3.2.4.1 Blood samples 
Blood samples were taken by venipuncture at admission (I-IV), and on days 1, 2, and 
7 after admission (I), or on days 1, 2, 3, 7, 14, and 21 after admission (III) unless the 
patient was discharged earlier from hospital. Blood samples for flow cytometry and 
for plasma measurements were anticoagulated with pyrogen-free acid-citrate-dextrose 
(ACD) (Terumo Europe N.V., Leuven, Belgium) (II, III, IV). Immediately after 
withdrawal, these samples were cooled in an ice-cold water bath and then kept at 0 °C 
until processed for flow cytometry within 24 hours. From the rest of the sample, 
plasma was separated by centrifugation at +4 °C and stored in aliquots at –70 °C. 
Blood samples for serum measurements were taken concurrently. After coagulation 
and centrifugation of these samples, they were either tested directly as a part of the 
hospital laboratory routines (II, IV), or the aliquots of serum were frozen and stored at 
−20°C (I). 
3.2.4.2 Flow cytometry 
Measurement of phagocyte surface marker expression was done with a FACSort flow 
cytometer and CellQuest software (Becton Dickinson, San Jose, CA, USA). CD11b 
expression was measured in neutrophils and monocytes (IV) and HLA-DR expression 
in monocytes (II, III, IV). 
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Reagents 
Monoclonal antibodies (mAb) were as follows: anti-CD14 fluorescein isothiocyanate 
(FITC) conjugated mAb (IgG2b, clone MFP9), anti-HLA-DR phycoerythrin (PE) 
conjugated mAb (IgG2a, clone L243), anti-CD11b PE-conjugated mAb (IgG2a, clone 
D12), and mouse IgG2a PE-conjugated mAb. FACS lysing solution was used for cell 
washing and red cell lysing. All reagents were from Becton Dickinson. 
Cell labelling 
Paired 25-µl aliquots of each blood sample were stained with saturating 
concentrations of mAbs. To measure monocyte surface marker expression, the first 
sample was double-labelled with FITC-conjugated anti-CD14 mAb and PE-
conjugated anti-HLA-DR mAb or anti-CD11b PE-conjugated mAb, and the other 
sample with FITC-conjugated anti-CD-14 mAb and PE-conjugated irrelevant mouse 
IgG2a mAb. For neutrophil CD11b expression measurements, the first sample was 
labelled with anti-CD11b PE-conjugated mAb and the other with PE-conjugated 
irrelevant mouse IgG2a mAb. After staining, the non-bound mAb molecules were 
removed by washing, then red cells were lysed with FACS lysing solution, and the 
cell pellet was resuspended in ice-cold 0.5% formaldehyde in saline. 
Measurement of expression 
Monocytes were identified on the basis of their CD14-positive fluorescence and light-
scatter properties, and neutrophils based on their light-scatter properties.  CD11b 
antigen expression was determined from 5 000 neutrophils and 2 000 monocytes, and 
results were presented in relative fluorescence units (RFU), which was the geometric 
mean channel of the CD11b PE fluorescence histogram.  
 
HLA-DR antigen expression of monocytes was evaluated by determining the HLA-
DR fluorescence intensity of monocytes (II) and the proportion of positively 
fluorescing monocytes (II, III, IV). An HLA-DR histogram and a mouse IgG2a 
(control) histogram of 2000 monocytes were developed. Monocyte HLA-DR 
fluorescence intensity, expressed as RFU, was obtained by subtracting the median 
channel number of the IgG2a histogram from the median channel number of the 
respective HLA-DR histogram. The proportion of HLA-DR-positive monocytes was 
measured in two ways: Firstly, by a threshold method (II) an electronic gate was set 
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manually so that it included the brightest 3 to 5% of the cells stained with mouse 
IgG2a mAb. Then the same gate served to determine the proportion of positively 
fluorescing cells in the respective sample stained with anti-HLA-DR mAb. 
Laboratory technicians unaware of each patients’ clinical status performed this step. 
Secondly, by a modified histogram subtraction method (Overton 1988) (II, III, IV) the 
control histogram (mouse IgG2a) was smoothed and then subtracted from the 
respective HLA-DR histogram (Figure 2). The histogram differential represents HLA-
DR-positive monocytes, the proportion of which was calculated by CellQuest 
software. 
3.2.4.3 Immunoassays and other laboratory tests 
Serum tryptase measurements were done with fluoroimmunoassay UniCAP Tryptase 
(Pharmacia & Upjohn, Uppsala, Sweden) (I). Plasma levels of IL-1ra, IL-4, IL-10, 
and IL-11, and serum levels of VEGF and bFGF were determined by enzyme-linked 
immunosorbent assay (ELISA) kits (Quantikine, R&D Systems, Minneapolis, MN, 
USA) (I, III, IV). Plasma levels of IL-13 were determined by ELISA kit (CytElisa, 
Alpco Diagnostics, Windham, NH, USA) (III). Plasma levels of IL-1β, IL-6, and sIL-
2R were determined by a chemiluminescent immunoassay (Immulite, DPC, Los 
Angeles, CA, USA) (III, IV). Plasma procalcitonin levels were determined by 
immunoluminometric assay (LUMItest, Brahms Aktiengesellschaft, Berlin, 
Germany) (IV). All measurements were done according to the manufacturers’ 
protocols. Serum levels of AST, calcium, creatinine, CRP, glucose, LDH, urea, and 
blood haematocrit, leucocyte, and platelet counts were determined as part of hospital 
laboratory routines (II, IV). 
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Figure 2. Flow cytometric determination of proportion of HLA-DR-positive 
monocytes by channel-by-channel subtraction. The control histogram () was 
overlaid by and subtracted from the HLA-DR histogram (). An electronic gate (M1) 
was set at the intersection. The differential histogram (dotted area) indicates the 
proportion of HLA-DR-positive monocytes (65%). RFU, relative fluorescence units. 
 
3.2.5 Statistical analysis 
Results were expressed as median and inter-quartile range (IQR). For comparisons of 
three groups, the Kruskall-Wallis test (II, III), Cuzik's test for trend (II), or the 
Jonkheere-Terpstra test for trend (III) were used. Comparisons between two groups 
were done with the Mann-Whitney U test (I, III, IV). P-values were adjusted by the 
Bonferroni method; P-values less than 0.05 were considered significant (I-IV). The 
time course of inflammatory mediators was tested with Friedman’s test (I, III), with 
Dunn’s test used in post hoc comparisons (I). Fisher’s exact test (I) or chi-square tests 
(III) were used to compare proportions of patients between two groups. Study of 
correlations between cytokine levels and monocyte HLA-DR expression was done by 
Pearson correlation and linear regression analysis (III). The Spearman rank 
correlation coefficient served in determining the relationship between percentage of 
HLA-DR-positive monocytes and HLA-DR fluorescence intensity (II), and in 
studying correlations between marker levels and interval to development of organ 
failure (IV). Agreement of the proportion of HLA-DR-positive monocytes between 
repeated measurements by the threshold method and between the threshold method 
and channel-by-channel subtraction method were evaluated with the intraclass 
correlation coefficient and its 95% confidence interval (CI) (II). Logarithmic 
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transformation or exponential transformation allowed normalisation of distributions of 
predictors when necessary (III, IV). Logistic regression analysis was used to find 
independent predictors (III, IV). To study whether combined markers provided better 
prognostic accuracy, the markers were combined with the Boolean operator ‘or’ (III, 
IV). 
 
Optimal cut-off values for markers, with the corresponding sensitivities, specificities, 
and positive and negative likelihood ratios with 95% CI were determined by receiver 
operating characteristic (ROC) curves (II, III, IV).  Areas under the ROC curves 
(AUC) (II, III, IV) with corresponding 95% CI were calculated (II, IV). The 
diagnostic odds ratio with 95% CI (IV) or accuracy (III) was determined for each 
predictor at the optimal cut-off level. The optimal cut-off point of a ROC curve is the 
point at which the slope R satisfies the equation R = C/B × (1 − P)/P, where C is net 
cost of treating non-diseased individuals, B is net benefit of treating diseased 
individuals, and P is prevalence of disease. An estimation of C/B ratio was made, and 
the cut-off point for each marker was selected at which R = 1, which is equivalent to 
the point where the sum of sensitivity and specificity was maximized (IV) (Cantor et 
al. 1999).  
 
Comparison of sensitivities and specificities was done by the method described by 
Newcombe (2001) (IV). This method displays point and 95% CI of differences in 
sensitivity and specificity (∆) between two paired tests weighted by mixing parameter 
λ (range 0–1) (λ= 1/(1 + R)), which takes into account the prevalence together with 
C/B ratio. 
 
3.3 Results 
3.3.1 Mast cell tryptase, VEGF, and bFGF (I) 
Of the 70 patients studied, tryptase levels were within normal limits (<13.5 µg/l) in 65 
(93%) patients at all time points. However, the peak tryptase level was above the 
upper normal reference limit in 4 of 21 AP patients with organ failure but in only one 
of 49 patients without organ failure (P=0.026). Peak levels of tryptase were 
significantly higher in patients with organ failure (6.6 µg/l, IQR 4.8 to 12.6) than in 
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patients not developing organ failure (4.0 µg/l, IQR 2.7 to 6.2) (P=0.018). 
Furthermore, at day 2 after symptom onset, tryptase level was higher in organ-failure 
patients (6.0 µg/l, IQR 4.5 to 7.4) than in patients who did not develop organ failure 
(3.4 µg/l, IQR 2.3 to 4.7) (P=0.006). Serum concentrations of VEGF and bFGF were 
within normal limits at admission, but levels increased towards the end of the 
observation period (P<0.001), and in post hoc comparisons, day 7 concentrations 
were significantly higher than concentrations on days 0, 1, and 2 (P<0.001 and 
P<0.05, respectively). The time-course of VEGF and VEGF levels for each day in 
organ-failure patients and other patients were similar. 
3.3.2 Monocyte HLA-DR expression in predicting organ failure (II) 
The two methods, the channel-by-channel subtraction method and the threshold 
method, were evaluated for proportion of HLA-DR-positive monocytes. The 
intraclass correlation coefficient for the two assays was 0.96 (95% CI 0.95-0.97). The 
channel-by-channel subtraction method was preferred to the threshold method and 
used in further analysis, because it resulted in more reproducible values than did the 
threshold method. Monocyte HLA-DR expression decreased significantly with 
increased disease severity, as shown in Table 5. The proportion of HLA-DR-positive 
monocytes correlated with HLA-DR fluorescence intensity (r=0.89; 95% CI 
0.86-0.91). 
 
Table 5. Monocyte HLA-DR expression from 310 patients with AP at admission to 
hospital 
 Group I Group II Group III  
HLA-DR expression ( n=194) ( n=87) (n =29) P value 
Positive monocytes (%)  90 (80, 95) 84 (66, 91) 62 (49, 76) < 0.001 
Density (RFU)  90 (53, 143) 65 (34, 115) 20 (13, 49) < 0.001 
Values are median (IQR). P values were obtained by Cuzik’s test for trend and adjusted by Hommel’s method. 
Group I, patients with mild AP; Group II, patients with severe AP, but no organ failure; Group III, patients with 
severe AP and subsequent organ failure. RFU, relative fluorescence units. 
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Figure 3. Development of organ failure during the first 7 days after hospital 
admission and after symptom onset in 29 patients with severe AP and subsequent 
organ failure. 
 
 
Of the 29 patients with organ failure, in 27 (93%) it developed within the first week 
and in 13 (45%) within 24 h of admission (Figure 3). In predicting organ failure at 
admission, areas under the ROC curve for the percentage of HLA-DR-positive 
monocytes, HLA-DR fluorescence intensity, APACHE II, and CRP were a respective 
0.78 (95% CI 0.66-0.87), 0.81 (0.71-0.89), 0.79 (0.69-0.86), and 0.80 (0.69-0.88). 
Table 6 shows optimal cut-off values with corresponding sensitivities, specificities, 
and positive likelihood ratios for the variables. 
 
Table 6. Performance of the variables in predicting organ failure in patients with 
acute pancreatitis at admission to hospital 
Measurement Cut-off value Sensitivity (%) Specificity (%) PLR 
HLA-DR expression     
   Positive monocytes  78% 83 (64 - 94) 72 (67 - 77) 3.0 (2.2 - 3.8) 
   Density  33 RFU 69 (49 - 85) 84 (79 - 88) 4.3 (2.9 - 6.1) 
APACHE II score  7 76 (56 - 90) 73 (67 - 78) 2.8 (2.0 - 3.6) 
CRP  57 mg/l 83 (64 - 94) 74 (68 - 79) 3.2 (2.5 - 4.1) 
Values in parentheses are 95% CI; PLR, positive likelihood ratio; RFU relative fluorescence units 
 
3.3.3 Anti-inflammatory response and immunosuppression (III) 
Plasma concentrations of IL-6 (Figure 4A), IL-10 (Figure 4B), and IL-1ra (Figure 4C) 
increased significantly along with increasing disease severity at days 0, 1, 2, 3, and 7. 
During follow-up, plasma concentrations of IL-10 in Groups II and III were highest at 
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day 0 and then decreased by day 3 (P<0.001, Friedman’s test), whereas the respective 
IL-6 and IL-1ra concentrations did not differ significantly between days 0, 1, 2, and 3. 
IL-4, -11, and -13 levels were below the detection limit in most of the samples (data 
not shown). Monocyte HLA-DR expression decreased significantly along with 
increasing disease severity at days 0, 1, 2, 3, 7, and 14 (Figure 4D).  
 
 
Figure 4. Plasma concentrations of IL-6 (A), IL-10 (B), and IL-1ra (C) and 
percentage of HLA-DR-positive monocytes (D) at days 0, 1, 2, 3, 7, 14, and 21 after 
hospital admission. Patients with mild AP (Group I)   , severe AP patients not 
developing organ failure (Group II)     , and organ-failure patients (Group III)     . 
Box-whisker plots show median, interquartile range, highest and lowest values, 
outliers, and extremes. Dashed line is sensitivity level of the assay. N is number of 
patients. Statistical significance for trend between the three groups at different time-
points: * P < 0.01, ** P < 0.001, n.s. = not significant. 
 
 
The proportion of HLA-DR-positive monocytes at day 2 correlated with peak IL-1ra, 
IL-6, and IL-10 concentrations during days 0, 1, and 2 (r = −0.47, r= −0.65, r= −0.67, 
respectively; P<0.001 each). In stepwise linear regression analysis, both IL-6 and 
  
 
53
IL-10 were independent predictors of monocyte HLA-DR expression (P=0.013 and 
P=0.003, respectively), and these explained 50% of the variability of HLA-DR 
expression. The prevalence of severely depressed monocyte HLA-DR expression 
increased along with disease severity and was highest among patients with secondary 
infections (Table 7). For each of the nine patients with infectious complications, a 
control patient was chosen. Controls were matched by length of hospital stay and by 
group. The percentage of HLA-DR-positive monocytes value did not differ 
significantly at its nadir between infected patients and controls: median 27% (IQR 
16%-45%) versus 36% (24%-50%), P=0.354, but it did differ at day 14: 32% 
(23%-61%) versus 65% (40%-80%), P=0.035; n=7, and at day 21: 49% (36%-69%) 
versus 83% (62%-96%), P=0.025; n=6. 
 
Table 7. Clinical outcome in relation to lowest level of monocyte HLA-DR 
expression. Number of patients (%). 
 Level of monocyte HLA-DR expression 
(Percentage of HLA-DR positive monocytes) 
Outcome  (number of patients) Severe depression  
(<50%) 
Mild depression 
(50-80%) 
Normal 
(>80%) 
Mild AP (n=27) 0 (0%) 13 (48%) 14 (52%) 
Severe AP, no organ failure (n=27) 13 (48%) 13 (48%) 1 (4%) 
Severe AP with organ failure (n=20) 16 (80%) 4 (20%) 0 (0%) 
Infectious complication (n=9) 8 (89%) 1 (11%) 0 (0%) 
 
 
By stepwise logistic regression analysis, both IL-6 and IL-10 were independent 
predictors of organ failure at admission. IL-6 >130 pg/ml or IL-10 >39 pg/ml 
predicted development of organ failure at hospital admission with a sensitivity of 
95%, and specificity of 88%. In diagnosing severe AP according to the Atlanta 
classification, independent predictors by logistic regression analysis were IL-10 and 
APACHE II. Admission IL-10 >12 pg/ml had a sensitivity of 91%, specificity of 
89%, and post-test probability of 84% in diagnosing severe AP. In patients with organ 
dysfunction, peak levels of IL-10 and IL-1ra were significantly higher in the six non-
survivors than in the fourteen survivors: median 122 pg/ml (IQR 110-342) versus 54 
pg/ml (29-117), P=0.017 and median 65.9 ng/ml (IQR 7.6-129.9) versus 5.7 ng/ml 
(3.1-9.4), P=0.032, respectively. The nadir proportion of HLA-DR-positive 
monocytes in organ-failure patients was 34% (IQR 23-47%), which did not differ 
significantly between non-survivors and survivors. 
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3.3.4 Early prediction of organ failure with combined markers (IV) 
Of the conventional markers, serum calcium, glucose, and creatinine were identified 
as the factors with independent significance (Table 8). Likewise, of the markers of 
inflammation, IL-10 and IL-6 independently predicted organ failure (Table 8). 
Finally, when these five predictors were applied to stepwise backward logistic 
regression analysis, only IL-10, glucose, and calcium were independent predictors of 
organ failure (Table 8).  
 
Table 8. Independent predictors of organ failure by logistic regression analysis 
Predictors      Odds ratio  P 
Conventional markers*    
     Calcium† 0.63  (0.5, 0.8) 0.001 
     Glucose‡ 12 (2.7, 58) 0.001 
     Creatinine§ 31 (2.6, 375) 0.007 
Markers of inflammation**    
     IL-6§ 4.7  (1.8, 12) 0.002 
     IL-10§ 5.5  (1.6, 18) 0.006 
Independent markers††    
     Calcium† 0.63  (0.5, 0.8) <0.001 
     IL-10§ 8.1  (2.4, 28) <0.001 
     Glucose‡ 6.2  (1.3, 30) 0.024 
Values in parentheses are 95% confidence intervals. *CRP, LDH, AST, creatinine, urea, glucose, 
calcium, and platelet count; **monocyte HLA-DR and CD11b expression, neutrophil CD11b 
expression, IL-1β, IL-1ra, IL-6, IL-10, sIL-2R, and procalcitonin; ††Calcium, glucose, creatinine, IL-6, 
and IL-10 were included in the analysis; †exp-transformed, ‡natural log-transformed, §10-base log-
transformed 
 
 
The regression model: g(X) = −4.117 + 2.097 × log10(X1) − 0.47 × exp(X2) + 1.821 × 
ln(X3), where X1 is plasma IL-10 concentration, X2 is serum calcium concentration, 
and X3 is serum glucose concentration had a larger AUC (0.91; 95% CI 0.85 - 0.98) in 
ROC analysis than did IL-10, calcium or APACHE II (Figure 5). IL-10 >50 pg/ml or 
calcium <1.65 mmol/l was the best marker combination (Figure 5, Table 9). This 
combination had a positive predictive value of 56% and a negative predictive value of 
99%. Respective values for the logistic regression model at the optimal cut-off point 
were 51% and 98%. The combination of IL-10 and calcium had significantly better 
diagnostic accuracy than IL-6 (when cost/benefit ratio, C/B, was less than 0.18), 
IL-10 (when C/B was more than 0.044), calcium (when C/B was less than 0.17) or 
APACHE II (when C/B was more than 0.028) (Figure 6). 
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Figure 5. ROC curves for the regression model with IL-10, calcium, and glucose, and 
for IL-10, calcium, and APACHE II. The symbol represents sensitivity and specificity 
of a combination of IL-10 >50 pg/ml or calcium <1.65 mmol/l. Arrows show optimal 
cut-off points for the regression model (−0.55), IL-10 (>27.2 pg/ml), calcium (<1.82 
mmol/l) and APACHE II (7). AUC, area under curve. 
 
 
Table 9. Diagnostic performance of predictors 
Predictor Cut-off Sensitivity (%) (95% CI) 
Specificity (%) 
(95% CI) 
PLR 
(95% CI) 
NLR 
(95% CI) 
Odds ratio 
(95% CI) 
IL-10 or calcium >50 pg/ml or <1.65 mmol/l 88 (71, 96) 93 (85, 97) 12 (6.0, 25) 0.13  (0.05, 0.33) 94 (26, 345) 
Regression model* >−0.55 82 (64, 92) 92 (84, 96) 10 (5.0, 20) 0.20  (0.10, 0.41) 51 (16, 159) 
Calcium <1.82 mmol/l 67 (48, 81) 94 (87, 97) 11 (4.8, 25) 0.36  (0.22, 0.58) 31 (10, 92) 
IL-6 >132 pg/ml 73 (54, 86) 91 (83, 95) 8.0 (4.1, 15) 0.30  (0.17, 0.52) 27 (10, 75) 
LDH >750 U/l 77 (58, 90) 86 (77, 92) 5.7 (3.3, 9.7) 0.26  (0.14, 0.50) 22 (8, 60) 
IL-10 >27.2 pg/ml 79 (61, 90) 85 (76, 91) 5.2 (3.2, 8.6) 0.25  (0.13, 0.48) 21 (8, 56) 
Monocyte HLA-DR <78% 82 (64, 92) 75 (65, 83) 3.2 (2.2, 4.7) 0.24  (0.12, 0.50) 13 (5, 36) 
Glucose >8 mmol/l 79 (61, 90) 78 (68, 85) 3.5 (2.4, 5.3) 0.27  (0.14, 0.53) 13 (5, 34) 
Monocyte CD11b >210 RFU 87 (68, 96) 66 (55, 75) 2.5 (1.8, 3.5) 0.20  (0.08, 0.51) 12 (4, 39) 
APACHE II 7 76 (57, 88) 78 (68, 85) 3.4 (2.2, 5.2) 0.31  (0.17, 0.57) 11 (4, 28) 
CRP >108 mg/l 70 (51, 84) 83 (74, 89) 4.1 (2.5, 6.6) 0.37  (0.22, 0.62) 11 (4, 27) 
Creatinine >98 µmol/l 70 (51, 84) 83 (74, 89) 4.1 (2.5, 6.6) 0.37  (0.22, 0.62) 11 (4, 27) 
Urea >5 mmol/l 84 (66, 94) 66 (56, 75) 2.5 (1.8, 3.4) 0.24  (0.11, 0.55) 10 (4, 29) 
sIL-2R >710 U/ml 85 (67, 94) 62 (51, 71) 2.2 (1.7, 2.9) 0.25  (0.11, 0.56) 9 (3, 25) 
IL-1β >2.65 pg/ml 79 (61, 90) 69 (58, 77) 2.5 (1.8, 3.5) 0.31  (0.16, 0.60) 8 (3, 21) 
AST >45 U/l 88 (71, 96) 51 (40, 61) 1.8 (1.4, 2.2) 0.24  (0.09, 0.61) 7 (2, 23) 
Platelet count <152 x109/l 58 (39, 74) 83 (74, 89) 3.4 (2.0, 5.7) 0.51  (0.34, 0.77) 7 (3, 16) 
Procalcitonin >1.1 ng/ml 73 (54, 86) 72 (62, 80) 2.6 (1.8, 3.7) 0.38  (0.22, 0.67) 7 (3, 16) 
Neutrophil CD11b >260 RFU 77 (57, 89) 62 (51, 72) 2.0 (1.4, 2.8) 0.38  (0.19, 0.73) 5 (2, 14) 
IL-1ra >930 pg/ml 82 (64, 92) 53 (42, 63) 1.7 (1.3, 2.2) 0.35  (0.16, 0.73) 5 (2, 13) 
*Logistic regression model of IL-10, calcium, and glucose; PLR, positive likelihood ratio; NLR, negative likelihood ratio 
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Only calcium level correlated significantly with onset of organ failure (Spearman´s 
rank correlation coefficient = 0.449, P=0.026). In the subgroup of patients with 
symptoms for less than 24 hours before hospital admission, levels of IL-6 and IL-10 
differed significantly between organ failure cases and control patients: median 57 
(IQR: 36-588) versus 11 (5-48) pg/ml for IL-6 (P=0.035), and median 65 (30-196) 
versus 8 (4-18) pg/ml for IL-10 (P=0.002), respectively. 
 
 
 
Figure 6. Difference (∆) in sensitivity and specificity weighted by λ of two tests and 
its 95% confidence interval (shaded area). A. Difference between combination of IL-
10 >50 pg/ml or calcium <1.65 mmol/l and IL-6 >132 pg/ml; B. Difference between 
combination of IL-10 >50 pg/ml or calcium <1.65 mmol/l and IL-10 >27.2 pg/ml; C. 
difference between combination of IL-10 >50 pg/ml or calcium <1.65 mmol/l and 
calcium <1.82 mmol/l; D. difference between combination of IL-10 >50 pg/ml or 
calcium <1.65 mmol/l and APACHE II  7. Dashed vertical line shows λ-levels 
where lower 95% confidence limit crosses zero. λ-level at intersection and 
corresponding cost/benefit ratios (C/B) where significant difference is present are 
shown. 
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3.4 Discussion 
3.4.1 Mast cell tryptase, VEGF, and bFGF (I) 
Increased vascular permeability and development of tissue oedema are 
pathognomonic features of AP. In mild AP, oedema is confined to the pancreas and 
peripancreatic tissues, whereas in severe AP complicated with organ dysfunction, the 
development of massive systemic oedema is common. Strong evidence has 
accumulated that mast cell activation may promote endothelial barrier dysfunction by 
releasing pro-inflammatory cytokines such as TNF-α (Thorlacius et al. 1994, Kubes 
and Granger 1996). In addition, mast cells upon activation release histamine, 
prostaglandins, and tryptase, all of which can promote the inflammatory reaction. 
Furthermore, activation of peripheral mast cells induces remote organ dysfunction in 
the lungs (Mukundan 2001), and in many models of experimental AP (Yonetci et al. 
2001, Dib et al. 2002a, 2002b), mast cells have been implicated in the systemic 
manifestations of AP. In the present investigation, the peak tryptase levels were 
higher in patients with organ dysfunction than in patients with mild AP or severe AP 
with local complications only. Interestingly, these levels were also higher at day 2 
after onset of symptoms in patients who later developed lung injury than they were in 
patients without subsequent remote organ dysfunction. This finding raises the 
question whether in AP, tryptase, a potent agonist of vascular endothelium (Molino et 
al. 1997, Coughlin 2000), contributes to the development of remote organ 
dysfunction. The origin of increased levels of tryptase is unclear. Tryptase may 
originate from the activated mast cells from inflamed pancreatic tissue or from 
activated lung mast cells in particular, as lung is a rich source of mast cells. Thus, 
severe AP may lead to activation of lung mast cells, which would release tryptase 
along with other pro-inflammatory mediators. However, whether the tryptase is 
derived from the pancreas or lung or both, the result would be increased permeability 
of the lung endothelium barrier, leading to organ damage. 
 
Although increased serum VEGF levels in organ-failure patients were expected, we 
were unable to observe any relationship between VEGF levels and disease severity. 
However, a significant increase in VEGF concentration at day 7 after admission was 
evident, and the time-course of the increase resembled that of bFGF, indicating their 
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involvement in the pancreatic regeneration process. Since all patients with organ 
dysfunction experienced respiratory failure, and this developed earlier than did 
increase in VEGF concentrations, it is unlikely that systemic release of VEGF plays a 
major role in alteration of pulmonary microvascular permeability and development of 
the lung injury in AP.  
 
The difference in tryptase levels between patient groups, although significant, 
appeared marginal and at hospital admission was not significant. In short, the results 
showed that for clinical AP neither serum tryptase nor VEGF seems to be a useful 
prognostic marker. 
3.4.2 Anti-inflammatory response and immunosuppression (II, III) 
At the early stage of severe AP, a reactive state in the blood develops, which is 
characterised by the co-occurrence of pro-inflammatory cytokines, anti-inflammatory 
cytokines, and emerging immune suppression, as defined by depressed monocyte 
HLA-DR expression. In the present investigation (III), an early and sustained 
elevation in IL-1ra, IL-6, and IL-10 plasma levels in patients with severe AP was in 
accordance with that of earlier studies (Brivet et al. 1999, Mayer et al. 2000). The 
highest level of IL-10 was detected at admission and decreased thereafter, whereas 
IL-1ra and IL-6 levels did not differ significantly during the first 4 days. In contrast to 
Chen and co-workers (1999), we detected no IL-11 in most of the patients; levels of 
IL-4 and IL-13 also proved to be low and showed no logical pattern in relation to AP 
severity. 
 
Monocyte HLA-DR expression was depressed significantly along with increasing 
severity of AP (II, III). This early decrease in expression in patients with severe 
disease is in accordance with earlier findings (Ricter et al. 1999, Kylänpää-Bäck et al. 
2001b). HLA-DR expression was already depressed at admission in patients with 
subsequent organ failure (II, III) and reached its nadir by day 2 after admission (III). 
Possible factors that reduce its expression may include IL-10, because IL-10 promotes 
intracellular retention of HLA-DR molecules in monocytes (Koppelman et al. 1997, 
Fumeaux and Pugin 2002). In other clinical disorders including sepsis and burn injury 
(Lin et al. 1994, Sachse et al. 1999), an inverse correlation occurs between circulating 
IL-10 level and monocyte HLA-DR expression. We found that in patients with AP, 
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HLA-DR expression was related inversely to IL-10 level, and, in addition, to the 
levels of IL-6 and IL-1ra; but only IL-6 and IL-10 independently predicted its 
expression in multiple linear regression analysis (III). Monocytes with low HLA-DR 
density show functional defects (Döcke et al. 1997, Wolk et al. 2000) which may lead 
to increased susceptibility to infections. Indeed, AP patients in a sustained anergic 
state are more susceptible to secondary infections than are non-anergic controls 
(Garcia-Sabrido et al. 1989). In accordance with this, we and others (Satoh et al. 
2002) showed that failure to recover initially depressed monocyte HLA-DR 
expression by the end of the second week was related to secondary infection (III). 
Moreover, no secondary infections occurred in patients with normal expression (III). 
In contrast to previous findings, low monocyte HLA-DR expression was not related to 
fatal outcome in organ-failure patients (III). 
 
Of the several methods used to measure monocyte HLA-DR expression (Livingston et 
al. 1988, Hershman et al. 1990, Wakefield et al. 1993, van den Berk et al. 1997, 
Ditschkowski et al. 1999, Sachse et al. 1999, Giannoudis et al. 1999), none has 
established a gold standard for measurement of the surface density of HLA-DR 
molecules. The threshold method, commonly used to determine the proportion of 
HLA-DR-positive monocytes with flow cytometry, is subjective, because the lowest 
level of positive fluorescence is set manually. In patients with decreased HLA-DR 
density, the control and test histograms have considerable overlap, rendering the 
threshold method unreliable (Overton 1988, Lampariello 1994, Watson 2001). The 
histogram subtraction method has thus been proposed as an objective option (Overton 
1988). We showed that the proportion of HLA-DR-positive monocytes can be 
measured objectively with the histogram subtraction method and that the proportion 
correlated with HLA-DR fluorescence intensity, each of which show a similar 
correlation with clinical outcome (II). However, the correlation plot  (II, Figure 3) 
revealed that a few samples show a considerable discrepancy between the HLA-DR-
positive proportion of monocytes and HLA-DR fluorescence intensity. Thus, neither 
of the two methods used to define monocyte HLA-DR expression appears to be 
perfect. 
 
Higher anti-inflammatory cytokine IL-6 and IL-10 levels appear in patients with fatal 
AP than in patients who recover (Brivet et al. 1999, Mayer et al. 2000). In accordance 
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with this, plasma IL-10 level at day 1 and peak IL-10 level were both significantly 
higher in non-survivors than in survivors (III). A similar difference was evident also 
in IL-6 levels, although was not significant. Furthermore, we found significantly 
higher IL-1ra levels in patients with fatal AP than in surviving patients (III). A 
number of experimental studies suggest that in AP, the anti-inflammatory cytokines 
IL-10, IL-6, and IL-1ra may have a protective effect (Norman et al. 1995a, Gloor et 
al. 1998, Cuzzocrea et al. 2002). The paradoxical relationship between high 
circulating levels of anti-inflammatory cytokines and severe disease can be explained 
by the compartmentalization of cytokine production: Anti-inflammatory activity takes 
place in circulating compartments, whereas in tissues such as the lungs, a pro-
inflammatory state appears to prevail (Cavaillon et al. 2001, Dugernier et al. 2003). 
Because locally produced pro-inflammatory mediators induce an anti-inflammatory 
counter-reaction in the blood, circulating levels of anti-inflammatory cytokines may 
thus reflect the overall severity of the inflammatory response syndrome, whereas the 
pro-inflammatory reaction in tissues eventually determines patient outcome. 
 
In summary, levels of circulating anti-inflammatory cytokines may reflect systemic 
activation of the inflammatory response, and their high levels are related to organ 
failure and possibly to fatal outcome. The initial inflammatory challenge in early 
severe AP is countered by the “compensatory anti-inflammatory response syndrome” 
(Bone 1996), which is characterised by a decrease in HLA-DR expression on 
peripheral blood monocytes and an impaired immune response. The anti-
inflammatory state reflects the disease severity and is related to secondary infection in 
the later course of the disease, but is not related to early death from non-septic 
multiple organ failure. 
3.4.3 Prediction of organ failure (II, III, IV) 
Most organ failure develops during the first week of AP. We found it to begin to 
develop after the end of the second day after disease onset, and nearly half the organ 
failures manifested during the first day of hospital admission. This early development 
has important implications for the current use of severity markers for AP, for the 
search for novel predictors of organ dysfunction, and for the design of therapeutic 
studies aimed at altering the course of systemic inflammation in AP in order to 
prevent the development of organ failure (Johnson et al. 2001). Organ failure 
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predictors thus need to be measured within hours of admission, and preferably within 
the first 2 days after symptom onset. 
 
Multi-factorial scoring systems like the Ranson score (Ranson et al. 1974) and 
Glasgow scores (Blamey et al. 1984) require follow-up for 48 hours, which negates 
their use in AP as predictors of organ failure. The advantage of APACHE II is that it 
requires no follow-up, but it may be too complex to accomplish in clinical practice on 
admission to hospital (Toh et al. 2000). In the present study, a number of single 
markers were equal to APACHE II, or were even better in predicting organ failure (II, 
III, IV). 
 
In AP, immunosuppression develops so early that monocyte HLA-DR expression can 
serve as a predictor of organ failure. Expression determined either by proportion of 
HLA-DR-positive cells or by HLA-DR fluorescence intensity predicted organ 
dysfunction at admission as well as did CRP or APACHE II (II, IV). However, the 
positive likelihood ratio was lower than 5 for these three markers, indicating only a 
small change in probability and little advantage in clinical decision-making (Windsor 
2000). Furthermore, the optimal cut-off for proportion of HLA-DR-positive 
monocytes (78%) in predicting organ failure at admission was far from lowest level 
(median 34%). Similarly, cut-offs for CRP (57 mg/l in II or >108 mg/l in IV) at 
admission were not near peak levels (median 345 mg/l in patients with severe AP, 
Mayer et al. 2002). These levels appeared not infrequently after, and not before, 
occurrence of organ failure. Due to their relatively slow time course, HLA-DR and 
CRP thus may not be ideal markers in its prediction.  
 
Time of presentation and possibly individual differences may affect levels of 
cytokines or other markers. Combining predictors may have reduced the impact of 
these effects; we found that combining markers improved prediction of organ failure. 
Among anti-inflammatory cytokines, the combined markers (IL-6 >130 pg/ml or IL-
10 >39 pg/ml) provided better sensitivity than did any single cytokine (III). Among 
conventional markers of severity and inflammation markers together the best 
combined markers were IL-10 >50 pg/ml or calcium <1.65 mmol/l, a combination 
with a positive likelihood ratio (12), negative likelihood ratio (0.13), and odds ratio 
(94) better than any of the single markers. The combination of IL-10 and calcium had 
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significantly better sensitivity (88%) and specificity (93%) than did any of the single 
markers or APACHE II when compared together and weighted by a clinically relevant 
C/B ratio (IV). In clinical practice, this combined test may have a great impact on 
decision-making and may in future provide a means by which to select patients who 
might benefit from special treatment modalities. 
 
Levels of cytokines rise early in the course of both experimental and clinical severe 
AP (Van Laethem et al. 1998, Mayer et al. 2000), which facilitates their use as early 
predictors of organ dysfunction. In the current study, patients who developed organ 
failure had significantly elevated IL-6 and IL-10 levels compared to levels of other 
patients with AP within the first 24 hours of symptom onset (IV). At admission, these 
tests predicted development of organ failure equally well, having positive likelihood 
ratios over 5 (III, IV). Furthermore, IL-10 was one of the independent predictors of 
organ failure in logistic regression analysis involving 19 prognostic markers (IV). In 
predicting severe AP according to the Atlanta classification, IL-10 >12 pg/ml at 
admission showed very good diagnostic accuracy (90%) and post-test probability 
(84%) (III). It may be that circulating IL-10 levels reflect the initial activation of 
systemic inflammation in AP that ultimately leads to organ dysfunction, and so IL-10 
represented an early independent predictor of organ dysfunction. 
 
Serum calcium level appeared to be the best single marker in predicting organ failure 
(odds ratio 31), but in accordance with earlier findings (Kawa 2000), subgroup 
analysis showed that this was not true until 24 hours after symptom onset. Calcium 
and other conventional markers predictive of clinical organ failure later in the course 
of AP may not be predictive in terms of pathophysiology but rather may reflect the 
presence of organ dysfunction. Massive vascular leakage is one of the main 
pathophysiological events preceding organ failure (Lehr et al. 2000). Increased 
vascular permeability facilitates sequestration of circulating calcium and albumin into 
the extracellular space, resulting in hypocalcaemia (Bhattacharya et al. 1985, 
Carlstedt et al. 2000). A correlation of calcium level with clinical onset of organ 
failure suggests that low calcium levels may denote microvascular dysfunction and 
therefore ongoing organ dysfunction that will soon manifest itself clinically. 
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In conclusion, early development of organ failure in AP suggests that its prediction 
should take place as early as upon hospital admission. The best single predictor of 
organ failure among a number of predictive tests available in routine clinical practice 
is serum calcium. Combined with serum calcium, IL-10, an early marker of systemic 
inflammation, is superior to single markers in predicting organ failure in AP, and this 
combination test could be of considerable value in clinical practice. 
3.4.4 Importance of inflammatory state in future treatments 
Despite increased knowledge of the pathogenesis of AP and of multiple organ 
dysfunction syndrome, little progress has occurred in treatment of patients with severe 
AP. To affect the clinical course of AP, we need to be able to identify the patient at 
risk for developing organ dysfunction very early, then to attempt to modulate the early 
pro-inflammatory response, then to abolish the subsequent immunosuppression later 
in the course of the disease. The current study presented a method with combined 
markers for early identification of these patients at risk. Although a number of anti-
inflammatory mediators for modulation of early pro-inflammatory response are at 
present available, data from clinical trials involving AP are limited, and an optimal 
drug or combination of them for this purpose remains to be established. However, 
because a considerable number of patients with AP seek medical help only after a 
relatively long delay after symptom onset, the therapeutic window for modulating the 
early pro-inflammatory response may be too narrow (Johnson et al. 2001). Future 
trials with anti-inflammatory drugs should probably concentrate on those patients 
admitted within the first 24 hours after onset of AP, when organ dysfunction has not 
yet begun to develop. In addition, those patients who develop organ failure and 
survive the first week might be candidates for immunostimulatory therapy, aimed at 
preventing secondary infections and late mortality.  
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3.5 Conclusions 
1. Mast cell activation may play a role in the development of remote organ 
dysfunction in patients with AP. However, in clinical AP, neither serum 
tryptase nor VEGF may serve as predictors of organ dysfunction. 
 
2. Anti-inflammatory response in AP developed early and may in part be 
responsible for development of immunosuppression. A strong initial anti-
inflammatory response was related to organ failure and fatal outcome. IL-6 
and IL-10 may be useful in prediction of organ failure as early as within the 
first 24 hours of disease onset.  
 
3. Organ failure developed early in the course of AP, not infrequently during the 
first day of hospital admission. Prediction of organ failure should therefore 
take place within hours of admission. At hospital admission, monocyte HLA-
DR expression predicted organ failure as well as did CRP and APACHE II 
score, however, IL-10 combined with serum calcium was superior to single 
markers or APACHE II score in predicting organ failure in AP, and thus may 
offer valuable support in clinical decision-making. 
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